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INTRODUCTION TO THE STUDIES 
Cystic Fibrosis (1-4) is the most common lethal genetic disease in Caucasians 
occuring in approximately 1 :2500 live births, but is very rare among Orientals and 
native African negroes. The condition is transmitted as an autosomal recessive 
trait and heterozygotes do not express the disease. Since Cystic Fibrosis (CF) is 
an autosomal recessive trait and it may be assumed that virtually all patients will 
be identified as such, a heterozygous carrier frequency among whites is estimated 
to be between 1:20 to 1:30 (5). It is still impossible to detect the heterozygous 
state. 
CF was first recognized as a distinct disease by Anderson in 1938 (6). Since then, 
the clinical manifestations of the disease have been well described. The disease 
affects the exocrine gland secretions throughout the body (4). These secretions 
show one or more abnormalities; an altered electrolyte content, a diminished 
water content and/or changed rheologic properties due to anomalous 
macromolecules. Clinically, the disease is characterized by exocrine pancreatic 
insufficiency and chronic obstructive pulmonary disease both secondary to 
obstruction by inspissated secretions of the mucous glands (4). The diagnosis CF 
is usually made by the detection of elevated concentrations of sodium and 
chloride in the sweat in the setting of gastro-intestinal and pulmonary disease. A 
family history of CF is of diagnostic assistance (7). Despite intensive research, 
however, the nature of the primary defect has still been incompletely elucidated. 
Pulmonary infection is the major cause of morbidity and mortality in patients with 
CF (4). The lungs appear normal at birth. Eventually, the poor clearance of 
viscous mucus promotes colonization and infection by microorganisms. This 
initiates a chronic cycle of inflammation, mucous hypersecretion and bronchial 
obstruction finally leading to damage of the bronchial wall with abcess formation, 
bronchiectases and fibrotic foci. Complications of the pulmonary disease include 
pneumothorax, hemoptysis and pulmonary hypertension with cor pulmonale. As 
a result lung function deteriorates and most patients succumb to the 
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consequences of respiratory insufficiency. Since the first description of CF, 
median survival has increased to more than 20 years today and the quality of live 
has improved as a result of more complete understanding of the pathophysio-
logy and advances in therapy, in particular antimicrobial treatment (1). 
Bacteria are the most important microorganisms responsible for progression of 
lung pathology (8). Bacteria most frequently involved are Haemophilus influenzae, 
Staphylococcus aureus, Pseudomonas aeruginosa, and Pseudomonas cepacia. 
H. influenzae and S. aureus are often seen at an early stage while P. aeruginosa 
becomes more frequent with increasing age (9). The introduction of effective 
drugs against H. influenzae and S. aureus has improved the prognosis of CF 
remarkably since the 1950's. Since then P. aeruginosa has become the most 
frequent and most important pulmonary pathogen. In recent years, a progressive 
increase in the isolation rate of P. cepacia has been observed. Since P. cepacia 
is resistant to many antimicrobial drugs and also results in greater impairment of 
pulmonary function than does P. aeruginosa, in some centres, this microorganism 
has become a major clinical problem (10, 11). 
Viral infections are no more frequent in patients with CF than in the normal 
population, but it has been shown that they can induce acute bacterial 
exacerbations (12). Although colonization with Candida species is not uncommon 
and precipitins to Aspergillus are occasionally found, invasive fungal infections in 
CF are rare (8). 
P. aeruginosa is by far the most important pulmonary pathogen in CF. Its 
prevalence is reported to be 30 to 90 percent (9). The original source, the main 
route of transmission and the factors which determine colonization are still 
unknown. Once acquired, this microorganism is seldom eradicated, although it 
may disappear temporarily from the sputum during treatment. Since P. aeruginosa 
is a well-known cause of nosocomial infections, the question of cross-
colonization/infection has been discussed frequently (13-17). Studies monitoring 
sputum cultures from patients at summer camps showed that the risk of cross-
colonization/infection was low or even undetectable. In contrast, siblings with CF 
generally harbour P. aeruginosa strains of the same types. This does not 
necessarily prove that cross-colonization/infection has occurred, rather that 
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siblings may have acquired the bacteria from a common source. 
In the lungs of patients with CF, P. aeruginosa undergoes an environmental 
adaptation characterized by production of large amounts of mucoid 
exopolysaccharide (MEP) and by changes in somatic antigens and susceptibility 
to serum (18). The MEP in which microcolonies are embedded frustrates 
phagocytosis and contributes significantly to the secretion of high amounts of 
lysosomal enzymes by polymorphonuclear leukocytes (PMNs) (19-21). These 
enzymes are believed to cleave immunoglobulins (and immune complexes), 
complement components and complement receptors on PMNs, together resulting 
in an impaired phagocytosis. Moreover, in patients colonized by P. aeruginosa for 
a longer period of time most of the antibodies to outer membrane structures 
belong to nonopsonizing lgG subclasses which also negatively affect 
phagocytosis. Changes in somatic antigens during colonization are thought to be 
responsible for a shift from opsonic to nonopsonic antibody isotypes. The high 
levels of PMN-derived lysozomal enzymes in the lungs are in imbalance with their 
inhibitors resulting in proteolytic tissue damage. This is believed to be the primary 
cause of lung tissue destruction. Most patients with CF produce high 
concentrations of circulating antibodies to P. aeruginosa. Poor prognosis has 
been shown to be associated with a pronounced antibody response. 
Susceptibility to human serum may explain why P. aeruginosa never becomes 
bacteraemic in CF patients. 
The management of patients with CF is still based on the objectives and methods 
first described by Anderson (6) namely to ensure optimal nutrition and to prevent 
or control pulmonary infection. Although antimicrobial therp.py has significantly 
improved the prognosis of CF, no consensus has yet been reached on the goals 
and rationale of antibiotic treatment (22). There are disagreements about the 
indications for therapy, the drug or drugs to be used, the route of administration, 
the dosage schedule, and the duration of treatment. In some centres, for 
instance, only acute exacerbations are treated while in others, patients are given 
antimicrobial therapy periodically or even continuously. Additionally, the 
parameters to monitor the effect of treatment appear to differ from centre to 
centre. 
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Many drugs, including antibiotics, are more rapidly eliminated from the circulation 
by patients with CF than by controls (23-25). These findings led to the suggestion 
that antimicrobial treatment could be more effective when it was based on the 
pharmacodynamics and pharmacokinetics of antibiotics in patients with CF rather 
than the normal dosage schedules. Exacerbations of chronic respiratory infections 
caused by P. aeruginosa are usually treated with an aminoglycoside in 
combination with an antipseudomonas B-lactam antibiotic or a quinolone (26). 
Combination therapy is often given because it seems to offer better results than 
monotherapy, possibly due to synergistic interaction in relation toP. aeruginosa 
(27,28). Furthermore, resistance to combination therapy is believed to develop 
less rapidly (27). In addition to antimicrobial therapy, other supportive measures 
such as physiotherapy, coughing techniques and inhalation of mucolytic or 
bronchodilatating agents are used. Because of the inability to control pulmonary 
infection in CF with antibiotics, new therapies are being evaluated. These include: 
anti-inflammatory agents, immunomodulators, vaccines and monoclonal 
antibodies (29-32). 
The ecology and susceptibility of P. aeruginosa and the pharmacokinetics and 
pharmacodynamics of tobramycin in patients with CF are subjects of study in this 
thesis. 
Current knowledge of the typing of P. aeruginosa and difficulties in typing 
Pseudomonas isolates from patients with CF is discussed in chapter 1. The 
composition of the Pseudomonas flora in CF patients monitored over time by 
means of serotyping, active and passive pyocin typing and phage typing is 
described in chapter 2. The in-vitro activity of a number of antipseudomonas 
agents is presented in chapter 3, and in chapter 4 the in-vitro interactions between 
tobramycin and three antipseudomonas B-lactam antibiotics are investigated by 
means of checkerboard titrations. In particular the effect of using various antibiotic 
dilution series was determined, the implications of which are discussed in chapter 
5. 
The results of a pharmacokinetic study of tobramycin in CF patients of different 
ages is reported in chapter 6. The data from this study were used to formulate 
guidelines for adequate and safe dosage of this antibiotic in CF. Whether or not 
application of these guidelines leads to better clinical results than those achieved 
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with conventional dosage schemes is explored in chapter 7. In chapter 8 the 
results obtained from our pharmacokinetic and pharmacodynamic studies are 
evaluated in relation to those reported in the literature. 
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Chapter 1 
PSEUDOMONAS AERUGINOSA IN CYSTIC FIBROSIS: EPIDEMIOLOGICAL 
INVESTIGATIONS 
Horrevorts AM\ Borst J3 , Kerrebijn KF2 and Michel MF1 
Departments of Clinical Microbiology and Antimicrobial Therapi and Pulmonary 
Medicine in Children2 (Sophia Children's Hospital), Erasmus University, 
Rotterdam; Special Department for Pseudomonas Research3, National Institute of 
Public Health and Environmental Hygiene, Bilthoven, The Netherlands. 
SUMMARY 
Pseudomonas aeruginosa is the most common pulmonary pathogen in patients 
with cystic fibrosis. Epidemiological s~udies using typing methods have failed to 
resolve the confusion about the main route of transmission, the prevalence of 
crossinfection, and the number of strains (types) which may colonize an individual 
patient. This may be due to the special properties frequently observed in isolates 
from these patients which affect the typing methods used. Several typing methods 
are evaluated for their potential as epidemiological tool for P. aeruginosa strains 
from patients with cystic fibrosis. 
INTRODUCTION 
P. aeruginosa has been identified as the most common and important pulmonary 
pathogen in patients with cystic fibrosis (CF) (1). The main route of transmission 
and the factors determining colonization are still unknown. Once acquired, this 
organism is seldom eradicated, although it may disappear temporarily from the 
sputum during treatment. Isolates of P. aeruginosa with differing morphological 
characteristics and antibiograms can be cultured from single sputum samples of 
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individual patients (2). These observations together with reported difficulties in 
typing CF isolates resulted in confusion about the number of types which might 
colonize an individual patient. Some reports have suggested that CF patients may 
be colonized by only a single type (2,3), while others reported colonization by two 
or more different types (4,5). Whether cross infection among patients with CF 
occurs or not remains also unclear (6-i 0). It is, however, conceivable that the type 
or types of P. aeruginosa present in the lungs of patients with CF in the course 
of time will be replaced by other type or types. Until now, few data are available. 
To gain an insight into these problems, epidemiological investigations are needed. 
Therefore, typing methods must be used in order to differentiate strains of P. 
aeruginosa from each patient and between patients. In this chapter several typing 
methods are evaluated for their potential as epidemiological tools for CF P. 
aeruginosa strains. Conventional techniques mostly performed are serotyping (0 
and H typing), pyocin typing and phage typing. Newer methods using cell 
membrane proteins and plasmid or chromosomal DNA fragments as an 
epidemiological marker are being introduced (11, 12). 
TYPING METHODS 
Serological typing: 0 antigens 
The peripheral part of the outer membrane of Gram negative bacilli consists of 
lipopolysaccharides (LPS), which comprise three parts; lipid A, the core region 
and a variable side chain ( = 0 antigen) (13). Variations in this side chain form the 
basis of serological typing (14). Seventeen distinct types have been described, for 
which specific 0 antisera are available (15). Whereas 90% of clinical isolates of P. 
aeruginosa can be assigned to a specific 0 type by agglutination techniques (16), 
this is possible in only one third of P. aeruginosa isolates from patients with CF. 
Approximately one half of CF isolates are agglutinated by more than one 0 
antiserum, and about one tenth do not react with any (17). The prevalence of 
polyagglutinating and nonagglutinating strains of P. aeruginosa in CF appears to 
increase with the duration of colonization (i 8). Strains exhibiting polyagglutinability 
possess less 0-antigen-containing LPS than do monoagglutinating strains (19,20), 
due to the fact that these strains have partly lost the polysaccharide portion of the 
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LPS (17). Thereby, the central core of the LPS which is normally covered with 
these polysaccharides, becomes exposed to antibodies (17,19). Non agglu-
tinability may be due to the loss of larger parts of the LPS structure (21). The 
sensitivity to fresh normal human serum and the loss of invasive virulence of both 
polyagglutinating and non agglutinating CF isolates may also be a consequence 
of deficiencies in the protective oligosaccharide specific side chains (17,22). The 
high frequency of polyagglutinating and nonagglutinating strains is a major 
problem in differentiating isolates of P. aeruginosa from patients with CF. To 
overcome the difficulties in serotyping, CF strains should be tested under different 
conditions (different growth temperatures in combination with different concentra-
tions of the 0 antisera). The postulate underlying this procedure is that in non- or 
polyagglutinating strains the LPS shows deficiencies but that intact structures 
more or less exist under different conditions (21). Since phage infection can 
influence 0 serotype, it would be informative to examine whether or not the 
phages are involved in the shift from mono-to poly- and nonagglutinating strains 
(23,24). 
An important phenotypic feature of the CF pseudomonas isolates is the 
production of mucoid exopolysaccharide. This mucoidy feature has been shown 
not to influence 0 typability or sensitivity to human serum (18,25). 
Serological typing: H Antigens 
The majority of P. aeruginosa strains are motile by means of a single polar 
flagellum. H typing has not been widely adopted for routine use perhaps because 
of the difficulties of preparing specific anti-flagellar sera. H typing can be useful in 
distinguishing between strains of the same 0 serotype. However, non flagellar 
strains are common in CF (26). Therefore this approach is not suitable. 
Pyocin typing 
Pyocins are antibacterial proteinaceous substances produced by P. aeruginosa. 
Three varieties of pyocins are produced by over 70 - 90% of clinical isolates, i.e. 
R pyocins, F pyocins and S pyocins (27-29). Production of and sensitivity to 
different pyocins vary considerably among strains and form the basis of pyocin 
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typing. Typability rates around 90% can be achieved (30). Two different methods 
are employed active and passive (30). In active pyocin typing, the pyocins 
produced by the test organism are tested for their antibacterial activity against a 
series of standard indicator strains. In the passive pyocin method, the procedure 
is reversed, so that the susceptibility of the test organism to a set of standard 
pyocins is determined. However results are influenced by the metabolic state of 
bacteria (31), and in CF isolates the production of mucus forms a barrier to 
pyocin activity (32). Modified typing techniques which are more efficient should 
then be performed (3,30). 
Phage typing 
A standard phage typing procedure for P. aeruginosa comprising 20 different 
phages was described by Asheshov (33). In general approximately 85% of all 
isolates are typable. However the technique is method dependent such that 
reproducibility can be as low as 60% (34). CF isolates have been shown to be 
less sensitive to lysis by the typing phages than are those from other patients 
(40% versus 85%) (35). In addition spontaneous loss of phage as well as phage 
infection may result in an altered susceptibility pattern (36). As with pyocin typing, 
production of mucus by the strains presents difficulties (34). Mucoid strains are 
less phage typable than non-mucoid strains (19% of mucoid CF isolates in 
contrast to 59% of non-mucoid CF strains) (35). Since phages "and pyocins both 
attach to the bacterial surface, it is of interest to know to what extent changes in 
outer membrane structure (such changes in outer membrane structure do occur 
in isolates of P. aeruginosa from patients with CF) affect the specificity of receptor 
sites. In summary phage typing has not proved to be a suitable method for the 
typing of strains from patients with CF. 
Plasmid or chromosomal DNA fragments and cell envelope proteins 
Plasmid or chromosomal DNA fragments and cell envelope proteins are being 
introduced as a marker for epidemiological investigations (11,12,37), and are 
currently being evaluated although plasmid typing is limited only to isolates which 
possess these DNA fragments. Since changes in outer membrane structure have 
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been reported for P. aeruginosa isolates from patients with CF, the value of the 
use of cell envelope proteins as an epidemiological marker needs further 
investigation. 
Epidemiological investigations 
Several conventional typing systems have been used in an attempt to address 
epidemiological questions concerning CF patients, such as the route of 
transmission, the prevalence of cross-infection, and the number of strains (types) 
which may colonize an individual patient. Contradictory results might be explained 
by the limitations of the methods used as well as the peculiar properties of P. 
aeruginosa strains obtained from these patients. For instance, simultaneous 
infection with mono-, poly- and non agglutinating isolates of P. aeruginosa has 
been interpreted as either infection with multiple types or infection with phenotypic 
variants of a single type. Furthermore, isolates that possess the same 0 serotype 
are not necessarily related. Therefore, a combination of (conventional) methods 
in particular serotyping and pyocin typing may be more productive in helping to 
understand the natural history of P. aeruginosa infection in CF at least until the 
newer methods have been established. 
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SUMMARY 
In this study, the composition of the Pseudomonas flora was monitored over time 
in 15 patients with cystic fibrosis. Sputum samples were obtained for culture over 
a period ranging from 2 to 60 months. Isolates of P. aeruginosa were typed with 
the aid of four different techniques: serotyping, active and passive pyocin typing, 
and phage typing. The maximum number of different serotypes found in the 
patients was three (one serotype in 9 patients; two serotypes in 5 patients; three 
serotypes in 1 patient). Pyocin and phage typing revealed no marked differences 
between strains of the same serotype in individual patients. An exacerbation of 
chronic respiratory infection was not associated with changes in the composition 
of the flora. These data show that the Pseudomonas flora in the lungs of patients 
with cystic fibrosis is constant over time. 
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INTRODUCTION 
In 30-50% of the younger and 70-90% of the older patients with cystic fibrosis 
(CF) the lungs are chronically colonized with P. aeruginosa (2). Disagreement 
exists about the number of types which may colonize an individual CF patient. 
Some authors have reported that these patients may be colonized by only a 
single type (15, 16), while others have suggested that two or more different types 
may be involved (3, 13). It is conceivable that, in the course of time, changes in 
the flora will occur and that one type will be replaced by another. In this study, 
the composition of the Pseudomonas flora was monitored over time in 15 patients 
with CF using serotyping, active and passive pyocin typing and phage typing. 
MATERIALS AND METHODS 
Patients 
Fifteen patients with CF comprised the study group. The diagnosis CF was based 
on increased sweat electrolyte levels (Na+ > 60 mmol/1) and characteristic 
gastrointestinal and pulmonary disease. The patients suffered from chronic 
pulmonary P. aeruginosa infection. Each patient was followed during three 
consecutive exacerbations (A, B, and C) in order to determine fluctuations in the 
composition of the Pseudomonas flora in the sputum. An exacerbation was 
defined as follows; increased cough and production of sputum, tachypnoea, 
dyspnoea and weight loss. For exacerbation A isolates from a sputum sample 
obtained on the day of hospital discharge were investigated. For exacerbation B, 
isolates from samples obtained during hospital stay were typed (day of admission 
and twice weekly thereafter), while for C isolates from a sample obtained on the 
day of hospital admission were used. Samples were obtained after physiotherapy. 
All exacerbations had taken place between november 1981 and march 1986. 
Patients were hospitalised and given antipseudomonal therapy consisting of a B-
lactam antibiotic in combination with an aminoglycoside. 
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P. aeruginosa strains 
Sputum was cultured such that different morphological types (14) could be 
isolated from the primary plate. Where possible, three colonies were selected from 
each morphological type and after identification (4) they were stored at -80° C 
until required. 
Serotyping 
Serotyping was performed by means of agglutination (7). Each clinical isolate was 
subcultured on two Tryptic Soy Agar (axoid) plates of which one was incubated 
at 30° C and the other at 37° C for 18 hours. After incubation the plates were 
handled separately as follows: the cell mass was removed with a cotton wool 
swab and suspended in saline. Both suspensions were steamed for 2V2 hours, 
then centrifuged and resuspended in fresh saline to a density of about 4x1 010 cells 
per ml giving two antigen suspensions (30° C Ag and 37° C Ag). 
a-antisera had been produced in rabbits (8) and each serum had been tested for 
cross-reactivity with other a-antigens. If these occurred, the serum was absorbed. 
Two different concentrations of antisera were used; 4 and 8 times the 
homologous titre (4.Ab and 8.Ab). Thus, there were four test conditions (i.e. 30° 
C Ag X 4.Ab, 30° C Ag x 8.Ab, 37° C x 4.Ab, and 37° C x 8.Ab). 0.025 ml Ag 
suspension was added to 0.025 ml Ab in a microtitre tray (Dynatek, U-bottom), 
the plate was sealed with tape, carefully shaken for 10 seconds, then incubated 
at 37° C. After 18 hours, each plate was read visually and interpreted thus; - no 
agglutination, ± weak agglutination, + agglutination, + + strong agglutination. The 
four different combinations were compared and the strongest agglutination 
reaction was recorded. To illustrate the method, the 4 agglutination patterns of 
two strains chosen arbitrarily are shown in table I. Strain 138P2 (patient #4) 
agglutinated most strongly and most often with a-antiserum 9 in all of the four 
patterns. Strain 112P13 (patient #5) had serotype 10 with an agglutination 
strength + in each of the 4 patterns. 
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Table I: Sero-typing patterns of P. aeruginosa strains 138P2 
(patient #4) and 112P13 (patient fl.5). The strains were typed 
under four different conditions (see materials and methods). 
Abbreviations: HT, homologous titre. 
Condition 
_I_ 
_I_I_ 
...1.!L _!L 
Incubation temperature 30° c 30oc 3r c 3r c 
of the strains 
+ + + + 
Titre of anti-sera 4x HT Sx HT 4x HT 8x HT 
Sero-typing 
results 
strain 138P2 2+,6+,9++ 9+,10+,11+ 9++ 2+,9++ 
strain 112P13 10+ 10+ 6:1:,10 10+ 
Table II: Codification of active pyocin typing results of P. 
aeruginosa strain 147P12 from patient #4 (see materials and 
methods). 
Indicator strain no. 2 3 4 5 6 7 8 
Growth inhibition of 
indicator strain by + + + + + + 
pyocins of 147P12 
Code 2 d 
29 
Only 2 of the 4 patterns included serotype 6 with an agglutination strength ± and 
+, respectively. 
Pyocin typing 
Active pyocin typing was performed according to the method described by Govan 
(5) using 8 indicator strains and passive pyocin typing according to the method 
described by Osman (11) using 8 indicator pyocins. Thus, in both typing 
procedures each strain was subjected to 8 tests which were coded as + = 
growth inhibition, and - = no growth inhibition. The resultant patterns of test 1 to 
3 and 4 to 6 were assigned a number; + + + =1, + +- =2, +-- =3, --- =4, -+-
=5, -+ + =6, --+ =7, +-+ =8, whereas the results of reactions 7 and 8 were 
assigned a letter; + + =A, +- =8, -- =C, -+ =D. An example is given in table II. 
Thus, the pyocin type of a strain was indicated by two figures followed by one 
letter. 
Phage typing 
Phage typing was done with the aid of the Colindale Typing Set (which comprised 
20 phages) using the method described by Asheshov (1). 
RESUlTS 
The results obtained in this study are summarized in table Ill. The study group 
comprised 9 females and 6 males with CF (no siblings) aged between 7 and 18 
years (column 1). The study period from exacerbation A to C ranged from 2 to 60 
months (column II). The number of sputum samples ranged from 5 to 12 samples 
(column Ill) and the number of morphologically different colonies of P. aeruginosa 
per culture from 1 to 7 (column IV). The total number of P. aeruginosa strains 
isolated and examined by the typing techniques is given in column V and ranged 
from 18 to 86. In 9 of 15 patients (#1 ,#2,#4,#6-#1 1) only 1 serotype was 
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detected (column VI). In 5 patients (#3,#5,#13-#15) 2 serotypes were found and 
in one patient (#12) 3 serotypes were present. In the patients whose sputum 
yielded more than one serotype, all serotypes were encountered in several 
samples, with the exception of strains with serotype 6 in patient #5 and again in 
patient #15 (column X). 
Active pyocin typing (column VII) revealed similarities as well as differences 
between serotypically identical strains from the same patient. The differences in 
active pyocin type between serotypically identical strains were based on minor, 
consistent differences or on the non-typability of strains (code 44C). This applied 
also to passive pyocin typing (column VIII). The number of different passive 
pyocin types within a serotype, however, exceeded the number of active pyocin 
types (column VII vs VIII). 
The phage type (column IX) of serotypically identical strains in the individual 
patients was either uniform (for instance patient #3 with serotype 1 with phage 
type pattern 21 + i 19X+352, and serotype 9 with phage type pattern 
16 + 21 + F8 + F1 0 + 1 09) or showed differences (for example the phage type 
patterns belonging to serotypes 2 and 8 found in patient #2 and #12, respec-
tively) within a given pattern of phages. An exacerbation of the chronic respiratory 
infection did not affect the composition of the Pseudomonas flora (sputum 
samples from exacerbation B versus A and C, column X). 
DISCUSSION 
In 30-50% of the younger and 70-90% of the older CF patients the lungs are 
chronically colonized with P. aeruginosa (2). Reports on the number of different 
types of P. aeruginosa that may infect the airways of the individual CF patients do 
not concur (3, 13, 15, 16). On the basis of differences in 0-antigen, P. aeruginosa 
strains can be serologically classified into 17 different types (8). In more than 90% 
of clinical isolates of P. aeruginosa (non-CF strains), a type-specific 0-antigen can 
be detected with type-specific 0-antisera (7). Serotyping of strains from CF 
patients is impeded by the fact that about 60% of the isolates react with more 
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than one type-specific 0-antiserum; only 30% show monoagglutination, and 10% 
agglutinate with none of the 17 antisera (12). Polyagglutinability is believed to be 
related to deficiencies in the lipopolysaccharide (LPS) (6). As a result, deeper 
structures of the LPS which are normally protected by the specific 0-antigens, are 
involved in the agglutination (10). Nonagglutinability may be due to the loss of 
larger parts of the LPS structure (6). In order to enhance discrimination between 
the various isolates, active and passive pyocin typing and phage typing were used 
in addition to serotyping in this study. One of the difficulties in these three typing 
methods is the mucoid character of the P. aeruginosa strains isolated from CF 
patients. This problem can in part be avoided by repeated transfer of the strains 
to solid media, causing partial dissociation of the mucoid to non-mucoid colony 
forms or by the use of modified techniques (7, 16). 
The aim of this study was to establish whether in the course of time the 
composition of the P. aeruginosa flora in the lungs of individual CF patients is 
subject to changes or whether it remains constant. For this purpose sputum 
samples from 15 CF patients were cultured over a defined period of time. The four 
typing techniques described were then applied in an effort to compare P. 
aeruginosa strains isolated from the same patient at different times. In view of the 
large number of polyagglutinable P. aeruginosa strains found in CF patients, 
agglutination was studied by serotyping under four different conditions (different 
growth temperatures used in culturing the strains in combination with different 
strengths of the 0-antisera). The postulate underlying this procedure was that in 
the polyagglutinable strains LPS shows deficiencies but that, in addition, there 
are also intact LPS structures in the wall, and that these can be detected with 
more or less evidence under different conditions (6). Of the strains tested, 20% 
proved to be monoagglutinable; 80% agglutinated with more than one a-
antiserum. Nonagglutinable strains were not found. Of each polyagglutinable 
strain the agglutinations obtained under the four different conditions were compa-
red. It was repeatedly found that one serotype predominated, either because this 
type prevailed andjor while it displayed the strongest agglutination. In addition, 
it was found that for a given patient strains of an identical serotype showed a 
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similar pattern of agglutinations. Also, the two pyocin typings and the phage 
typing revealed a largely homogeneous pattern, despite minor biological diffe-
rences between strains. If these results are taken together with those obtained by 
serotyping, the conclusion is warranted that the composition of the P. aeruginosa 
flora in the lungs of patients with cystic fibrosis remains fairly constant over time. 
In a study using DNA restriction fragments as an epidemiological marker, a similar 
observation was made in three patients with CF (9). 
REFERENCES 
1. Asheshov EH 197 4. An assessment of the methods used for typing strains 
of P. aeruginosa. In: Arseni A (Ed) Proceedings of the 6th International 
Congress of Bacteriolgy. Leontiadi Medical Editions, Athens, p 9-22. 
2. Cystic fibrosis foundation. Pulmonary infection in cystic fibrosis. "GAP" 
Conference Report 1983;7:4. 
3. Diaz F, Mosovich LL, Neter E. Serogroups of P. aeruginosa and the immune 
response of patients with cystic fibrosis. J Infect Dis 1970;11:269-274. 
4. Doudoroff M, Palleroni NJ. Pseudomonas. In: Buchanan RE, Gibbons NE 
(Eds) Bergey's mannual of determinative bacteriology 8th edn. The Williams 
and Wilkins Company, Baltimore, 1974;p 217-243. 
5. Govan JRW. Pyocin typing of P. aeruginosa. In: Bergan T, Norris JR (Eds) 
Methods in Microbiology. Academic Press, New York p, 1978;61-91. 
6. Hancock REW, Mutharia LM, Chan L, Darveau RP, Speert DP, Pier GB. P. 
aeruginosa isolates from patients with cystic fibrosis: a class of serum-
sensitive, non-typable strains deficient in lipopolysacharide 0 side chains. 
Infect lmmun 1983;42:170-177. 
7. Lanyi B, Bergan T. Serological characterisation of P. aeruginosa. In: Bergan 
T, Norris JR (Eds) Methods in Microbiology. Academic Press, New York 
1978;p 93-168. 
8. Uu PV, Matsumoto H, Kusama H, Bergan T. Survey of heat-stable, major 
somatic antigens of P. aeruginosa. lnt J Sys Bacteriol1983;33:256-264. 
36 
9. Ogle JW, Jada JM, Woods DE, Vasil ML Characterization and use of a DNA 
probe as an epidemiological marker for P. aeruginosa. J Infect Dis 
1987;1 :119-126. 
10. Ojeniyi B, Baek L, Hojiby N,. Polyagglutinability due to loss of 0-antigenic 
determinants in P. aeruginosa strains isolated from cystic fibrosis patients. 
Acta Path Microbiollmmunol Scand, Section B; 1985;93;7-13. 
11. Osman MAM. Pyocin typing of P. aeruginosa. J Clin Pathobiol1965;18: 
200-202. 
12. Pitt TL, MacDougall J, Penketh ARL, Cooke EM. Polyagglutinating and 
nontypable strains of P. aeruginosa in cystic fibrosis. J Med Microbial 
1986;21:179-186. 
13. Seale TW, Thirkill H, Tarpay M, Flux M, Rennert OM. Serotypes and antibiotic 
susceptibilities of P. aeruginosa isolates from single sputa of cystic fibrosis 
patients. J Clin Microbiol1979;9:72-78. 
14. Sheehan DJ, Janda JM, Bottone EJ. P. aeruginosa: changes in antibiotic 
susceptibility, enzymatic activity, and antigenicity among colonial 
morphotypes. J Clin Microbiol1982;15:926-930. 
15. Thomassen MJ, Demko CA, Boxerbaum B, Stern RC, Kuchenbrod PJ. Multip-
le isolates of P. aeruginosa with differing antimicrobial susceptibility patterns 
from patients with cystic fibrosis. J Infect Dis 1979;140: 
873-880. 
16. Williams RJ, Govan JRW. Pyocin typing of mucoid strains of P. aeruginosa 
isolated from children with cystic fibrosis. J Med Microbiol1973;6:409-412. 
37 

Chapter 3 
IN VITRO ACTIVITY OF NEW ANTIMICROBIAL AGENTS AGAINST 
PSEUDOMONAS AERUGINOSA ISOLATES FROM CYSTIC FIBROSIS 
PATIENTS 
Horrevorts AM 1 , Heeres-Weststrate PL1 , Kerrebijn KF2 and Michel MF1 
Departments of Clinical Microbiology and Antimicrobial Therapi and Pulmonary 
Medicine in Children2 (Sophia Children's Hospital), Erasmus University Rotterdam, 
The Netherlands. 
Published in the European Journal of Clinical Microbiology 1987,6:323-324. 
INTRODUCTION 
Chronic respiratory infections with Pseudomonas aeruginosa are encountered in 
30-50% of younger and in 70-90% of older patients with cystic fibrosis. To 
minimize progression of pulmonary destruction, acute exacerbations of this type 
of infection demand antimicrobial chemotherapy. At present many 
antipseudomonas drugs are available or under development, and we tested the 
activity of these agents against P. aeruginosa isolates from patients with cystic 
fibrosis. 
MATERIALS/METHODS AND RESULTS 
Each agent was obtained as a standard laboratory powder from the manufac-
turer and stored and handled as recommended. The 51 isolates of P. aeruginosa 
were recovered from sputum of 51 patients with cystic fibrosis. Non had received 
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intravenous chemotherapy during the four weeks before the sputum sample was 
obtained. The isolates, including mucoid and non-mucoid colony types, were 
identified biochemically by means of the API 20 NE identification system and 
maintained on tryptic soy agar slants at room temperature until tested. MICs were 
determined by an agar dilution technique. Freshly prepared serial twofold dilutions 
of antibiotic were incorporated into Diagnostic Sensitivity Test agar (Oxoid), giving 
final concentrations of 0.016 to 2048 mgjl. Plates were inoculated with a 
multipoint inoculator, which delivered a final inoculum of 104 CFU per spot (1 
microl of liquid) from overnight Mueller-Hinton broth cultures adjusted to 108 
CFU/ml (using a barium sulfate standard) and diluted 10·'. Inoculated plates were 
incubated at 35°C for 18 h. The MIC was the lowest concentration of antimicrobial 
agent which inhibited visible growth. One discrete colony or fine, barely visible 
haze was disregarded. P. aeruginosa ATCC 27853 was included as control 
organism in all sets of inoculations, and the MICs were consistent with established 
values within one twofold dilution. 
The results are summarized in Table 1. On a weight basis ciprofloxacin was the 
most active of the agents tested, inhibiting 82% of the isolates at 0.5 mg/1. At 
clinically attainable serum concentrations tobramycin and amikacin had similar 
activity. Within the penicillin group piperacillin was the most active drug. The 
activity of ticarcillin alone and ticarcillin plus clavulanic acid was equivalent. 
Cefsulodin and BMY 28142 had the lowest MIC50 values in the cephalosporin 
group; the amount of drug required to inhibit 75% of the isolates was 8 mgjl for 
each of the six cephalosporins tested. The monobactams aztreonam and 
carumonam had similar MIC50 values; only 12% of the strains tested were not 
inhibited by 32 mgjl carumonam. For 92% of the isolates the imipenem MIC was 
4 mgjl or less. No significant differences were seen in the activity of any drug 
against mucoid and non-mucoid strains. Cross-resistance between the penicillins, 
cephalosporins and monobactams was the rule. Although higher MICs of some 
drugs against isolates of P. aeruginosa from patients with cystic fibrosis have 
been reported (1-4) similar MIC ranges have also been documented (4-6). 
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CHEQUERBOARD TITRATION$: THE INFLUENCE OF THE COMPOSITION OF 
SERIALDILUTIONS OF ANTIBIOTICS ON THE FRACTIONAL INHIBITORY 
CONCENTRATION INDEX AND FRACTIONAL BACTERICIDAL 
CONCENTRATION INDEX 
Horrevorts AM', de Ridder CM', Poot MC', de Jonge MJA', Degener JE', Dzoljic-
Danilovic G', Michel MF' and Kerrebijn KF2 
Departments of Clinical Microbiology and Antimicrobial Therapy' and Pulmonary 
Medicine in Children2 (Sophia Children's Hospital), Erasmus University Rotterdam, 
The Netherlands. 
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SUMMARY 
Chequerboard titrations carried out with modified serial dilutions of antibiotics 
such that consecutive concentrations in these series were four times smaller than 
those in two-fold serial dilutions enable MICs and MBCs to be determined with 
greater accuracy. Interaction indices calculated by this method can differ markedly 
from those calculated on the basis of two-fold serial dilutions. The differences 
calculated in this study ranged from -0.30 to + 1.06. 
INTRODUCTION 
Interactions between antibiotics can be studied in vitro using chequerboard 
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titrations with serial doubling dilutions. More accurate determination of minimum 
inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) 
will in turn produce better estimates of the parameters used to measure the 
interaction between antibiotics, namely fractional inhibitory concentration indices 
(FIGs) and fractional bactericidal concentration indices (FBCis) (1). In order to 
investigate the value of these more accurate determinations, we have studied 
three combinations of antibiotics against Pseudomonas aeruginosa, determining 
FICls and FBCis using both conventional doubling dilutions and a modified 
dilution series giving smaller incremental concentrations. 
MATERIALS AND METHODS 
Bacterial strains 
Twenty-two strains of P. aeruginosa, isolated from sputa of 22 patients with cystic 
fibrosis were used. The strains were collected between October 1982 and October 
1983, identified (2) and stored after freeze-drying. Serotyping and pyocin typing 
showed that the isolates were unrelated. Twelve strains (nos 1 to 12) were tested 
with each of three combinations of antibiotics; ten (nos 13 to 22) were tested only 
with the combination ticarcillin plus tobramycin. P. aeruginosa ATCC 27853 was 
used as reference strain. 
Antibiotics 
Ticarcillin (Beecham), cefsulodin (Ciba-Geigy), ceftazidime (Giaxo) andtobramycin 
(Eli lilly & Co) were obtained in sterile, standardized powder form and stored at-
20°C until use. 
Medium 
lsosensitest Broth (Oxoid) was used. 
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Serial dilutions of antibiotics 
Serial dilutions were prepared from freshly prepared stock solutions in lsosensitest 
Broth of 2560 mgjl for ticarcillin, of 320 mg/1 for cefsulodin and ceftazidime and 
of 40 mgjl for tobramycin. The stock solutions were further diluted as shown in 
Table I. Proceeding from a single stock solution, several two-fold serial dilutions 
{A, B, C and D) were obtained. The concentrations together form a modified serial 
dilution in which the intervals between consecutive concentrations were four times 
smaller than those in a two-fold serial dilution. The extreme concentrations of the 
series were 0.25 and i 792 mgjl for ticarcillin, 0.; 25 and 224 mgjl for cefsulodin 
and ceftazidime, and 0.03 and 28 mgjl for tobramycin. The serial dilutions were 
checked with the reference strain for which the range of MICs of ticarcillin is 16-
32 mgjl {3), of cefsulodin and ceftazidime is 1.0-2.0 mgjl {4) and of tobramycin 
is 0.5-1.0 mgjl (3). 
Inoculum 
Shaken overnight cultures in lsosensitest Broth were adjusted to E600 nm=0.75 
and diluted i : i 000 in broth. Such dilutions contained 5xi 05 colony-forming units 
(CFU) per mi. 
MIC and MBC determination 
To 0.5 ml of each dilution of antibiotic 0.5 ml of the inoculum of a strain to be 
tested was added. After incubation of the cultures at 37°C for i 8 h the MIC of the 
antibiotic for the strain was read. The MIC was the lowest concentration at which 
no macroscopically visible growth of the strain was observed. To determine the 
MBC, 0.1 ml of each culture without visible growth was transferred to a blood 
agar plate. After incubation at 37°C for 24 h the number of colonies was counted. 
The MBC was the lowest concentration at which 99.9% of the number of CFU 
originally present per ml in the cultures had been killed. 
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Chequerboard titrations 
These were performed at the same time as the determinations of the MIG and 
MBC. In accordance with a chequerboard pattern 0.25 ml of each tobramycin 
concentration was combined with 0.25 ml of each concentration of a B-lactam 
antibiotic. Next, 0.5 ml of the inoculum of a strain to be tested was added to each 
combination. After incubation of the cultures at 37°C for 18 h end points were 
read and MBCs determined. 
Calculation of the degree of interaction between antibiotics in a 
chequerboard. 
FICis and FBCis were calculated in the usual way (1 ,5). 
Reproducibility of the chequerboard titrations 
To establish the reproducibility of the method used, the effect of two combinations 
(ticarcillin + tobramycin and ceftazidime + tobramycin) on three random strains 
was studied five times. The titrations were carried out on different days, always 
with freshly prepared serial dilutions of the antibiotics. 
Comparison of serial dilutions 
The FICis and FBCis obtained with the serial dilutions used in this study, were 
compared with those obtained using two-fold serial dilutions as in row A alone 
(Table I). 
Since several FICis and FBCis for a strain can be determined from a 
chequerboard, results were analyzed on the basis of both the lowest and the 
mean FICI and FBCI which could be calculated per titration. 
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Table I. Preparation of modified dilutions of 
tobramycin 
Stock Broth 
solutiona 
(volume units) 
4+6 = 
5+5= 
6+4= 
7+3= 
Concentrations 
(mg/1) 
16 --> 8 --> 4 etc. 
20 --> 10 --> 5 etc. 
24 --> 12 --> 6 etc. 
28--> 14--> 7 etc. 
aTobramycin standard= 40 mg/1. 
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0·5 
0·25 
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(b) 
-~-
0·125 0·25 0·5 
Cefsulodin FIC (FBC) 
Figure 1. Isobolograms of ceftazidime+tobramycin against isolate no. 6 (a), and cefsulodin+tobramycin 
against isolate no. 2 (b). FICI: e, two-fold dilutions; 0, modified dilutions. FBCI: V, two-fold dilutions; 
\l, modified dilutions. 
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RESULTS 
Table II lists the MICs and MBCs determined with modified serial dilutions of the 
antibiotics studied. Isolates nos 13 to 22, for which only ticarcillin and tobramycin 
MICs and MBCs were determined, had ticarcillin MICs >128 mgjl. To establish 
the reproducibility of chequerboard titrations using modified serial dilutions, the 
effect of ticarcillin + tobramycin and ceftazidime + tobramycin on three isolates 
(nos 2, 10 and 12) was studied five times. All titrations showed FICis and FBCis 
which never differed from the calculated mean by more than +0.15 or -0.15. This 
applied to the lowest as well as to the mean FICis and FBCis which could be 
calculated from the chequerboard titrations. Figure 1 (a) shows the isobolograms 
of the combination ceftazidime + tobramycin against isolate no. 6, and Figure 
1 (b) those of the combination cefsulodin + tobramycin against isolate no. 2. In 
figure 1 (a) a remarkable difference is demonstrated between the FICis determined 
with modified serial dilutions and those determined with two-fold dilutions of the 
antibiotics. Notable differences between the FBCis are shown in Figure 1 (b). 
For each of the isolates tested the differences were calculated between the FICis 
and FBCis found with the modified serial dilutions and those obtained with the 
two-fold serial dilutions. The calculated differences ranged from -0.30 to + 1.06. 
Table Ill lists these differences in classes of 0.15 both for the lowest and for the 
mean FICis and FBCis calculable from the chequerboard titrations. In only 8% of 
the cases the difference was negative, and this indicates that the FICis and FBCis 
obtained with the modified serial dilutions often exceeded those found with the 
two-fold serial dilutions. This applies in particular to the FBCis. Table Ill also 
shows that the distribution of the differences between the lowest values coincides 
with that of the differences between the mean values of the interaction indices. 
The differences between the strains 1 to 12 with ticarcillin MICs <128 mgjl and 
the strains 13 to 22 with ticarcillin MICs > 128 mgjl are likewise evenly distributed. 
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DISCUSSION 
FICis and FBCis are parameters which can be used to quantify the degree of 
interaction between antibiotics (1). According to Elion's equation a value below 
1 is suggestive of synergism, a value of 1 indicates addition, and a value above 
1 suggests antagonism (2,5). However, one seldom proceeds from these theore-
tical limits. The upper limit of synergism is generally an index of 0.5 in actual 
practice (6). 
The accuracy of MIC and MBC determinations depends not only on day-to-day 
variations (6) but also on methodological factors (7 -13) including the intervals 
between consecutive concentrations in the serial dilutions of antibiotics used (14). 
Accurate determination of MICs and MBCs will be reflected in parameters derived 
from them such as FIGs, FBCs, FICis en FBCis. 
In two-fold serial dilutions the sensitivity of the determination diminishes more with 
the increasing intervals between the higher concentrations than in the modified 
serial dilutions described here. On the other hand, the decreasing intervals 
between the lower concentrations more readily affect the reproducibility with 
modified serial dilutions. In view of these considerations chequerboard titrations 
would best be carried out with serial dilutions in which the intervals between 
consecutive concentrations would be constant (15). However, it is difficult to 
prepare such serial dilutions, and in addition, an unworkably high number of 
concentrations would be required to cover a sufficiently wide range. Serial 
dilutions containing concentrations as specified in the rows A and C (fabel I) 
should meet the objection mentioned above. The findings presented here indicate 
that strains for which a given combination of antibiotics shows a similar interaction 
index in two-fold serial dilutions, may differ significantly in index when examined 
with the aid of modified serial dilutions. This should be borne in mind when such 
strains are used for further studies on the basis of a "similar" interaction index 
(e.g. in animal models). Moreover, in clinical practice it is advisable to apply 
certain margins to interaction indices determined with two-fold serial dilutions of 
antibiotics. 
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Chapter 5 
ANTIBIOTIC INTERACTION: INTERPRETATION OF FRACTIONAl 
INHIBITORY AND FRACTIONAl BACTERICIDAl CONCENTRATION INDICES 
Horrevorts AM\ Michel MF' and Kerrebijn KF2 
Departments of Clinical Microbiology and Antimicrobial Therapy' and Pulmonary 
Medicine in Children (Sophia Children's Hospita1)2 , Erasmus University Rotterdam, 
The Netherlands. 
Published in the European Journal of Clinical Microbiology 1987,4:502-503. 
INTRODUCTION 
Interactions between antimicrobial drugs can be studied in vitro using 
checkerboard titrations. This is commonly done with serial doubling dilutions of 
drugs. When serial dilutions with smaller intervals between consecutive 
concentrations are used, minimum inhibitory concentrations (MICs) and minimum 
bactericidal concentrations (MBCs) can be determined with greater accuracy (1). 
More accurate determination of MICs and MBCs will be reflected in parameters 
derived from them, such as fractional inhibitory concentrations (FICs), fractional 
bactericidal concentrations (FBCs) and fractional inhibitory concentration indices 
(FICs) and fractional bactericidal concentration indices (FBCis) (2). 
FRACTIONAl CONCENTRATION INDICES 
The statement mentioned in the introduction may be elucidated by means of a 
hypothetical example. Using two-fold serial dilutions of antibiotics X and Y, let 8 
mgjl of X and 16 mgjl of Y be the lowest concentrations in combination inhibiting 
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Table 1: Preparation of a modified serial dilution (ex""l'le). Proceeding fran a single stock solution, 
several twofold serial dilutions (A, B, C and D) are obtained. The concentrations together form a mo· 
dified serial dilution in which the intervals between consecutive concentrations are four times smal-
ler than those in a twofold serial dilution. 
Stock # Broth Concentrations Row 
solution (RQ/l) 
(volune units) 
4 + 6 64 32 16 8 etc. A 
5 + 5 80 40 20 10 etc .. B 
6 + 4 96 48 24 12 etc. c 
7 + 3 112 56 28 14 etc .. D 
#Drug standard = 160 RQ/l. 
Table 2: Values of FIC!s (FBC!s) fran checkerboard titrations using twofold serial dilutions of drugs 
versus values (range) which might have been found if modified or semi-modified dilutions of drugs had 
been used. 
FICI (FBCI) 
(twofold di lutions)a 
2.00 
1.50 
1.25 
1.13 
1.06 
1.00 
0.75 
0.63 
0.56 
0.50 
0.38 
0.31 
0.25 
0.19 
0.13 
FICI (FBCI) 
(modified diluti ons>b 
1.25 . 3.20 
0.94 . 2.40 
0.78 . 2.00 
0.70 - 1.80 
0.66 - 1.70 
0.63 - 1.60 
0.47- 1.20 
0.39 - 1.00 
0.35 - 0.90 
0.31 - 0.80 
0.23 - 0.60 
0.20 - 0.50 
0.16 - 0.40 
0.12 - 0.30 
0.08 - 0.20 
~he concentrations of row A alone, see Table 1. 
ohe concentrations of rows A + B + C + D together, see Table 1. 
~he concentrations of rows A + C together, see Table 1. 
FICI (FBCI) 
(s,..i·modified dilutions)c 
1.50 - 2.67 
1.13 - 2.00 
0.94 - 1.67 
0.48 - 1.50 
0.80 - 1.41 
0.75 - 1.33 
0.56 - 1.00 
0.47 - 0.83 
0.42 - 0.75 
0.38 - 0.67 
0.28 - 0.50 
0.23 - 0.42 
0.19 - 0.33 
0.14 - 0.25 
0.09 - 0.17 
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the growth of a strain Z, where 32 and 64 mgjl are their respective MIGs when 
used alone. FIGs of X and Y deduced from these data will therefore equal 
8/32=0.25 and 16/64=0.25, the sum of these fractions giving an FIGI of 0.50. 
Using modified serial dilutions (Table i), 8 mg/1 of X and 16 mg/1 of Y may again 
be the lowest concentrations of the antibiotics in combination inhibiting the growth 
of strain Z. However, if the individual MIGs of X andY for strain Z now turn out to 
be 20 and 40 mgjl, the FIG value of X becomes 8/20=0.40 and ofY 16/40=0.40, 
resulting in an FIGI of 0.80. Thus, the use of modified serial dilutions of antibiotics 
X and Y caused an increase in FIGI from 0.50 to 0.80. 
Table 2 lists a number of FIGis (FBGis) calculated from fictional checkerboard 
titrations using two-fold serial dilutions of antibiotics, followed by the extremes of 
the values which might have been found for the FIGis (FBGis) if modified serial 
dilutions had been used. The table warrants three important conclusions. Firstly, 
using two-fold serial dilutions of antibiotics synergism cannot be assumed 
theoretically until the FIGI (FBGI) is less than 0.63. Secondly, the use of modified 
serial dilutions could show that differences/similarities in activity between various 
combinations of antibiotics found with two-fold serial dilutions do not exist or could 
show that such differences/similarities remain unnoticed in two-fold serial 
dilutions. Thirdly, apart from the given limits (3,4), an additive and antagonistic 
effect are difficult to detect with two-fold serial dilutions because with these 
dilutions the next value which the FIG (FBG) can assume after 1 is 2. 
In two-fold serial dilutions the sensitivity of the determination diminishes more with 
increasing intervals between the higher concentrations than in the modified serial 
dilutions. On the other hand, the decreasing intervals between the lower 
concentrations more easily affect reproducibility in modified serial dilutions. Serial 
dilutions containing concentrations as specified in the rows A and G (Table i) 
should satisfy the objections mentioned above. The last column of Table 2 lists 
the extremes of the values which might have been found for the FIGis (FBGis) 
given in the first column of Table 2 if these semi-modified dilutions had been 
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used. 
In clinical practice it is thus advisable to apply certain margins to interaction 
indices determined using twofold serial dilutions of antibiotics (fable 2). 
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SUMMARY 
The pharmacokinetics of tobramycin were evaluated in 15 patients (8 to 22 years 
of age) with cystic fibrosis (CF). A dose of 3.0 to 3.3 mgjkg of body weight was 
given intravenously over 20 minutes, and concentrations in serum were followed 
up to eight hours after initiation of the infusion. In the calculation of 
pharmacokinetic parameters, a two-compartment open model was used. The 
elimination half-life of the drug was highly inversely correlated with age 
(p<0.0004), and body weight (p<0.00002). Total Body Clearance (TBC), and 
Volume of distribution at steady state (Vdss) were directly correlated with age and 
body weight. However, when TBC and Vdss were corrected for Body Surface 
Area (BSA), no correlation could be demonstrated. The mean one-hour and eight-
hour serum concentrations of tobramycin were 5.40 and 0.45 mg/1. respectively. 
Between patients, considerable differences were found in the time after admini-
stration at which the serum concentration decreased below 1 mgjl. This interpa-
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tient variation has clinical implications for tobramycin therapy in CF, in particular 
for the dosing interval.-
INTRODUCTION 
Chronic respiratory infections with Pseudomonas aeruginosa are encountered in 
70 to 90 percent of patients with cystic fibrosis (CF)(1). Acute exacerbations are 
commonly treated with an aminoglycoside, often tobramycin, and an 
antipseudomonal B-lactam antibiotic such as ticarcillin (2,3). 
The Total Body Clearance (TBC) of a number of penicillin derivatives is unusually 
high in patients with CF. These penicillins have to be given more frequently or in 
a higher dosage than usual in order to ensure sufficiently protracted active serum 
concentrations (4-9). There are indications that the pharmacokinetics of 
aminoglycosides likewise deviate from the normal in CF. Frequent and high 
dosages are necessary to reach adequate serum concentrations (10-18). The 
amount of tobramycin required to control an exacerbation varies from patient to 
patient. This cannot be adequately explained by differences in severity of the 
disease or in the susceptibility of the bacterial flora to tobramycin. The therapeutic 
index of aminoglycosides is small in view of the possible ototoxic and nephrotoxic 
effects, and consequently safe and adequate administration of tobramycin is 
difficult, particularly in patients with CF. 
This study presents data collected on the serum tobramycin concentration-time 
curve in 15 patients with CF. The results are used to formulate guidelines on 
tobramycin dosing in CF. 
PATIENTS AND METHODS 
Study Population 
The study concerned 15 patients with CF, seven female and eight male patients 
ranging in age from 8 to 22 years. The diagnosis CF was based on increased 
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sweat electrolyte levels (Na+~60 mmol/1) and characteristic gastrointestinal and 
pulmonary disease. All patients required tobramycin and ticarcillin therapy for an 
acute exacerbation of their chronic respiratory infection caused by P.aeruginosa. 
During therapy, renal and auditory functions were determined regularly, and 
always found to be normaL Before the study, informed consent was obtained from 
all subjects and their parents. 
Serum Samples 
The serum tobramycin concentration-time curve was measured on the eighth or 
ninth day of therapy. A dose of 3.0 to 3.3 mgjkg of body weight was given 
intravenously over 20 minutes. Blood samples (1 ml) were drawn at times, t being 
0, i 0, i 5, 20, 25, 30, 35, 40, 50 minutes and 1, 11h, 21h, 4, 6 and 8 hours, from 
an indwelling plastic catheter in a forearm vein contralateral to the site of 
intravenous dosing. The samples were chilled to 4°C immediately. After 
centrifugation, the serum was stored at -80°C. Ticarcillin administration was 
discontinued 12 hours prior to the first sampling and then continued immediately 
after the last sampling. 
Tobramycin Assays 
Serum tobramycin concentrations were determined with an enzyme-immuno-
assay. All samples were tested in duplicate. The accuracy (19) of the method was 
checked in advance with test sera containing a known amount of tobramycin. The 
amount of tobramycin measured in the test sera deviated from the true amount 
by a maximum of 17 percent. The lower limit of detection for this assay was 0.20 
mg/1. 
Pharmacokinetic and Statistical Analysis 
A semilogarithmic plot of the concentrations of tobramycin vs time showed a 
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biexponential decay from the end of the infusion to the end of the dosing interval. 
Consequently, the data were analyzed according to a two-compartment open 
model. 
The following equations were used (20): 
(t2':T): 
for the post-infusion period: c,= ;"[1-e-·}-·',_,+ :13[1-e-"}e-"'-'' 
In this model, C1 is the serum concentration at time t (the mean serum 
concentration of tobramycin at t=O was 0.21 mgjl;'f, the infusion period; a and 
f3, rate constants; and A and B, intercept parameters. An estimate of the 
parameters A, a, B and {3 was obtained via a weighted least square adjustment, 
using the NUN procedure from the SAS computer program package (21). 
Of the derived parameters (t,. = half-life; AUC = Area Under the Curve; TBC = 
Total Body Clearance; Vdss = Volume of Distribution at steady state); the TBC 
and Vdss were calculated independent of the model used (22). Pearson's test 
was applied to investigate the significance of correlations between results (23). 
The p<0.05 was chosen as the level of statistical significance. 
RESULTS 
The serum concentrations in patient 1, eight years of age, and in patient 15, 22 
years of age, are plotted vs time in Figure 1. When studying all curves, the profile 
proves to change with age. With increasing age, the distribution (a) phase turns 
more quickly into the elimination ~ phase. In addition, elimination shows a faster 
decline. 
Individual patient characteristics and pharmacokinetic parameters are listed in 
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Table 1. The mean one-hour and eight-hour serum tobramycin concentrations are 
5.40 and 0.45 mgjl, respectively. All eight-hour (trough) concentrations are less 
than 2 mgjl. A 1 mg/1 level is attained between 2112 and 4 hours after the start of 
the infusion in five patients, between four and six hours in seven patients, and 
between six and eight hours in three patients (last column, Table 1). These 
differences are not related to the height of the one-hour serum tobramycin 
concentrations. 
The half-times of the distribution (t\-l<l) and elimination (t,_,6) phases are inversely 
correlated with age and body weight. A similar relationship is found for the 
AUG/Dose. The TBC and Vdss are directly correlated with age and body weight. 
However, correcting TBC and Vdss for BSA, no correlation could be demon-
strated. Linear coefficients of correlation are shown in Table 2. None of the 
pharmacokinetic parameters correlate with pulmonary function, i.e., FVC and 
FEV,. 
DISCUSSION AND CONCLUSIONS 
The serum concentration-time curve for tobramycin is characterized by a 
distribution (a) phase and a rapid (JJ) as well as a slow elimination ('Y) phase (24). 
During the distribution phase, the tobramycin serum concentration is determined 
mainly by the flow of the drug into the tissues and to a lesser degree by 
elimination. When a pharmacokinetic equilibrium is attained between blood and 
tissue compartments, the serum concentration of tobramycin becomes fully 
dependent upon elimination. The rapid elimination (/3) phase is determined by 
renal function, and if renal function is normal, the t, of this phase is about two 
hours (25). During the slow elimination ('Y) phase, which becomes visible in a 
curve about 24 hours after discontinuation of tobramycin therapy, the elimination 
is dependent upon the amount of tobramycin presented to the kidneys. This 
involves the slow release of very low concentrations of tobramycin from the deep 
tissues, i.e., the inner ear and the renal cortex (25). The t, of this phase is a few 
days (25). The total amount of tobramycin administered can be recovered 
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unchanged from the urine (25). 
In the CF patients described in this study, the serum concentrations oftobramycin 
were followed up to eight hours after a dose. A fresh dose of tobramycin was 
then given, and the interrupted administration of ticarcillin was resumed. Since the 
measured serum concentrations of tobramycin reflect the distribution (a) phase 
and the rapid elimination (/3) phase, the data were analyzed according to a two-
compartment open modeL Of the derived pharmacokinetic parameters of 
tobramycin, half-lives and AUC /Dose are highly age and body weight dependent 
For t,.6, a similar observation is made in neonates (26,27) and in non-CF children 
(28). The tl-!>a is influenced by both Vdss and TBC (t,.6"='VdssjTBC). In our patients, 
Vdss, as well as TBC, are increasing with age and body weight If increasing Vdss 
does not offset increasing TBC, t..a will decrease. 
Pharmacokinetic parameters of tobramycin have been collected in several studies 
of young patients with and without CF (i 3, i 5,; 8,26-30). After comparison of data, 
it would appear that both TBC and Vdss are greater in patients with CF than in 
those without. Because tobramycin is excreted primarily by the kidneys and is 
neither metabolized nor significantly protein bound (3i), a possible explanation for 
an increased TBC in CF could be an enhanced renal clearance. However, renal 
tobramycin handling of the same order was found in patients with CF and in 
control subjects (i 8). This suggests in CF alternative routes of excretion. Potential 
extrarenal clearance pathways are the respiratory and gastrointestinal tract 
Possible explanations for an increased Vdss include inflammation and 
inflammation-related pathology (32). 
Since the therapeutic index of tobramycin is small, efforts must be made to ensure 
safe and effective serum concentrations. With 3.0 to 3.3 mg tobramycinjkg of 
body weight given intravenously over 20 minutes, one-hour serum concentrations 
(Table 1) are reached that may be regarded as safe and adequate (33). On the 
other hand, between patients, considerable differences are found in the time after 
administration at which the serum concentration of tobramycin decreases below 
1 mgjL These findings have consequences for tobramycin therapy in CF, in 
particular for the dosing intervaL The risk of drug retention is least if the serum 
69 
concentration of tobramycin prior to each dose (trough level) is <2 mg/1 (34). In 
vitro, a concentration of 1 mgjl is able to inhibit the growth of between 50 and 90 
percent of isolates of P.aeruginosa (35). It may be assumed that given this 
concentration in the serum, the concentration of tobramycin in the bronchial tree 
will be considerably lower (36,37). In order to prevent toxic side effects of 
tobramycin, and simultaneously to ensure sufficiently protracted serum 
concentrations which may be expected to be therapeutically effective, in our CF 
patients, the dosing interval is adjusted to a trough level of 1 mgjl. Two days after 
initiation of therapy (3.3 mgjkg of body weight every eight hours), serum 
concentrations are measured at two, and again at six, hours after a dose. The 
values obtained are plotted semilogarithmically vs time. A straight line between 
the two points cuts the 1 mgjllevel at the desired dosing interval. This procedure 
postulates that the serum concentration-time curve for tobramycin between two 
and six hours after a dose takes a linear course in a semilogarithmic plot. Due to 
the later transition from distribution (a) phase to elimination (j3) phase, this is not 
the case in the youngest patients. So, the dosing interval estimated will be too 
long. On the other hand, in these patients, elimination takes a less steep course, 
and consequently, the risk of cumulation must be considered greater. In our 
opinion, this justifies the above procedure for the youngest patients as well. 
Adjustment in the dosing interval led in a number of our CF patients to a daily 
dose up to 26.4 mgjkg of body weight, i.e., 3.3 mg/kg of body weight every three 
hours. Although we have observed no toxic side effects of tobramycin to date, 
regular determination of serum concentrations (twice a week), as well as renal 
and auditory functions (once a week), remain necessary to monitor cumulation 
and toxicity of tobramycin. 
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Chapter 7 
TOBRAMYCIN IN PATIENTS WITH CYSTIC FIBROSIS: 
ADJUSTMENT IN DOSING INTERVAL FOR EFFECTIVE TREATMENT 
Horrevorts AM', de Witte J2 , Degener JE', Dzoljic-Danilovic G', Hop WCJ3 , 
Driessen 0 4 , Michel MF' and Kerrebijn KF2 
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Medicine in Children2 (Sophia Children's Hospital), Medical Statistics3 , Erasmus 
University, Rotterdam; Department of Pharmacology', State University of Leiden, 
Leiden, The Netherlands. 
Published in Chest '1987,92:844-848. 
SUMMARY 
The efficacy of the dosing regimen of tobramycin was investigated in 28 patients 
with cystic fibrosis (CF) who had an acute exacerbation of chronic pulmonary 
infection with Pseudomonas aeruginosa. The initial dose of tobramycin was 3.3 
mgjkg of body weight three times daily (i.e., 10 mgjkgjday). A highly significant 
relationship was found between the serum concentration of tobramycin 
immediately before a dose and the change in the Forced Expiratory Volume in 
one second (FEV,), both measured on the tenth day of treatment 
(r.=0.75;p<0.001). In nine of the 16 patients who had a six-hour serum 
concentration of 1 mgjl or less on the tenth day of treatment, the eight-hour 
dosing interval of tobramycin was shortened to achieve a serum concentration of 
tobramycin of about 1 mgjl prior to the next dose. In the other seven patients, the 
dosage of tobramycin was not changed. On the 20th day, seven of the nine 
patients in whom the dosing interval was shortened exhibited an increase in FEV, 
76 
of 20 percent or more. Such an increase was observed only in one of the seven 
patients in whom the dosing interval was not reduced (p <0.05). We conclude that 
individualizing the dosage of tobramycin in patients with CF results in a better 
clinical outcome. 
INTRODUCTION 
Thirty to 50 percent of the younger patients and 70 to 90 percent of the older 
patients with cystic fibrosis (CF) have a chronic pulmonary infection with P. 
aeruginosa (1). Acute exacerbations are commonly treated with an 
aminoglycoside in combination with an antipseudomonas B-lactam antibiotic (2). 
The Total Body Clearance of a number of antimicrobial agents, including amino-
glycoside and B-lactam antibiotics, is found to be increased in patients with CF, 
as compared with patients without CF (3-5). In order to ensure serum concen-
trations which may be expected to be therapeutically effective for patients with CF, 
the agents prescribed have to be given more frequently or in a higher dosage 
than usual (or both) (6,7). The therapeutic index of aminoglycosides is small in 
view of the possible ototoxic and nephrotoxic effects. The abnormal 
pharmacokinetics and the narrow therapeutic index make great demands on 
adequate and safe treatment with aminoglycosides in patients with CF. 
Within populations of patients with CF, a wide interpatient variation in Total Body 
Clearance of tobramycin has been observed (8,9). We investigated whether this 
variation determined the outcome of treatment. 
PATIENTS AND METHODS 
Studiepopulation 
Seventy-three patients with CF were admitted 246 times to the Sophia Children's 
Hospital in Rotterdam, the Netherlands, between January 1982 and July 1985. 
The diagnosis of CF was based on increased sweat electrolyte levels (Na+2:_60 
77 
mmol/1) and characteristic pulmonary and gastrointestinal disease. Criteria for 
eligibility in this study were the following: acute pulmonary exacerbation due to 
P .aeruginosa (the presence of other pathogens in the sputum in addition to 
P.aeruginosa was grounds for exclusion); chemotherapy consisting oftobramycin 
and ticarcillin intravenously based on the susceptibility pattern of the strains 
isolated from samples of sputum taken just before and during admission 
(Minimum Inhibitory Concentration [MIC] of tobramycin, ~2 mgjl; MIG of 
ticarcillin, ~64 mgjl); age at which pulmonary function can be measured reliably 
~6 years); and no accompanying conditions such as heart failure, pneumotho-
rax, and hemoptysis. In 46 (involving 28 separate patients) of the 246 admissions, 
these criteria of selection were fulfilled. For each of the 28 patients, only the first 
course of treatment after Jan 1, 1982 was involved in the study. 
Antimicrobial Therapy 
Treatment with antibiotics was started on the day of admission. A dose of 3.3 mg 
of tobramycin per kilogram of body weight was given intravenously over 20 
minutes every eight hours. Additionally, ticarcillin was administered in a dose of 
600 mg per kilogram of body weight per 24 hours; 300 mgjkg was given in a : 
continuous infusion and 75 mgjkg every six hours. The duration of antimicrobial 
therapy ranged from 19 to 26 days (mean, 21 days). 
Concomitant Therapy 
All patients received routine chest physiotherapy twice per day, including 
bronchial drainage, percussion, and coughing techniques, after the administration 
of a mucolytic aerosol (Mycomist, 20 mg in 4 ml of saline solution), to which 0.2 
mg of albuterol (salbutamol) was added. The patients' diet was adjusted, and they 
received supplementary vitamins and pancreatic enzymes. 
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Serum Concentrations of Tobramycin 
Serum concentrations were measured twice per week at one hour after the 
administration of a dose and prior to the administration of the next dose (predose 
serum tobramycin concentration). Concentrations were also measured two and 
six hours after administration on the 9th, 1Oth, or 11th day of treatment (referred 
to as the 10th day). 
The concentrations of tobramycin in the samples of serum were determined with 
an enzyme-immunoassay. The lower limit of detection for this assay was 0.20 
mgjl. The accuracy of the method was checked in advance with test sera 
containing a known concentration of tobramycin. The percentage of error of each 
result was calculated as follows: (true-reported/true) x 100. The accuracy (i.e., the 
mean percentage of error + 2 x standard deviation) was 9.6 percent, which can 
be graded as "good" by the criteria of Reeves and Bywater (10). 
Adjustment in Dosing Interval of Tobramycin 
An outline of the study is shown in Table 1. Adjustment in the dosing interval was 
dependent on the six-hour serum concentration of tobramycin measured on the 
tenth day of treatment. In patients in whom the six-hour serum concentration of 
tobramycin was more than 1 mgjl, initial dosage of tobramycin (i.e., 3,3 mgjkg 
every eight hours) was maintained. The dosage of tobramycin also was not 
altered in patients with a six-hour serum tobramycin concentration of 1 mgjl or 
less during admissions between Jan 1, 1982 and Oct 1, 1983; however, in such 
patients admitted between Oct 1, 1983 and July 1, 1985, on the tenth day of 
treatment, the dosing interval was shortened to achieve a predose serum 
tobramycin concentration of about 1 mg/1. This was done as follows (9): Serum 
concentrations at two and six hours after administration measured on the tenth 
day were plotted logarithmically against time. After a line was drawn through the 
two points, an estimate was made by extrapolation of how long after 
administration the concentration of tobramycin in the serum would reach the limit 
79 
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of 1 mgjl. This time was taken as the new dosing interval. The dose of 
tobramycin per administration was maintained at 3.3 mgjkg. Concomitant therapy 
and support of care were not altered during the whole period of study. 
Pulmonary Function 
The FEV, was taken as an indicator of the caliber of the airways. It was 
determined from a flow-volume measurement by integration of the maximal flows 
at the mouth. The highest value of three to five consecutive measurements was 
used. If the intrapatient variability of the consecutive measurements was 5 percent 
or less, FEV, was considered reliable. The FEV, was measured on admission and 
further twice per week during the time of treatment. Determination of FEV, was 
always within one hour after physiotherapy. The change in FEV, with respect to 
the FEV, measured on admission was calculated on the 9th, 10th, or 11th day of 
treatment (referred to as the tenth day). The change in FEV, after the 20th day 
with respect to the FEV, measured on the tenth day was determined on the 19th, 
20th, or 21st day (referred to as the 20th day). In accordance with studies with 
bronchodilating or bronchoconstricting agents, a change in FEV, of 20 percent 
or more was considered significant (11 ;12). 
Renal and Auditory Function 
As a consequence of the narrow therapeutic index of tobramycin, creatinine 
clearance using the method of Schwartz et al (13) and auditory function were 
checked regularly. These were always within normal limits in the patients involved 
in the study. 
Statistical Evaluation 
The Mann-Whitney U-test was performed to detect statistically significant 
differences of variables between grouped populations. Percentages were 
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compared by Fisher's exact test. Coefficients of correlation given were 
Spearman's. A reference to all methods is Snedecor and Cochran (14). 
RESULTS 
Twenty-eight patients with CF (17 female and 11 male patients), ranging in age 
from 6.5 to 19.5 years, were involved in the study. The patients were divided into 
two groups according to their six-hour serum concentration of tobramycin on the 
tenth day of treatment (Table 2). In 16 patients, this concentration was 1 mgjl or 
less; in 12 patients, it was more than 1 mgjl. Both groups did not differ 
significantly in terms of sex, age, height, weight, creatinine clearance on 
admission, one-hour serum tobramycin concentration on the tenth day, and FEV1 
on admission. Highly significant differences were found in the predose serum 
tobramycin concentration (p < 0.001) and the increase in FEV1 (p < 0.001 ), both on 
the tenth day. In the group of patients with a six-hour serum concentration of 
tobramycin greater than 1 mgjl, the mean predose serum tobramycin 
concentration and mean increase in FEV1 were 0.89±0.21 mgjl and 42.5±18.6 
percent, respectively, in contrast to 0.34 ± 0.11 mgjl and 8.4 ± 8.2 percent in the 
group of patients with a six-hour serum tobramycin concentration of less than 1 
mgjl. The predose serum tobramycin concentration vs change in FEV10 both on 
the tenth day, revealed a highly significant relationship (Fig 1;r.=0.75;p<0.001). 
However, there was no such correlation between the one-hour serum 
concentration of tobramycin and the change in FEV10 both on the tenth day was 
not found (r.=0.36;p>0.05). 
In nine of the 16 patients with a six-hour serum concentration of tobramycin of 1 
mgjl or less on the tenth day, the dosing interval of tobramycin was shortened 
to achieve a predose serum tobramycin concentration of about 1 mgjl. The 
adjusted intervals for these patients varied between three and six hours. In the 
other seven patients a dosing interval of eight hours was maintained. The patients 
in whom the dosing interval was shortened compared to those in whom this was 
not done were similar in terms of sex, age, height, weight, creatinine clearance on 
83 
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the tenth day, one-hour and predose serum tobramycin concentration on the 
tenth day, FEV, on admission, and increase in FEV, on the tenth day (Table 3). 
The mean increase in FEV, on the 20th day was significantly larger in the patients 
with a shortened dosing interval than in the patients with an unchanged dosing 
interval (34.0 ± 26.9 percent vs 8.1 ± 10.3 percent;p < 0.05). When the correlation of 
predose serum tobramycin concentration vs change in FEV,, both on the 20th 
day, was performed, a significant relationship was found (Fig 2;r.=0.60;p=0.01). 
A statistically significant correlation between one-hour serum tobramycin 
concentration and change in FEV,, both on the 20th day, could not be demon-
strated (r.=-0.31;p>0.1). 
In seven of the nine patients in whom the dosing interval was adjusted, an 
increase in FEV, of 20 percent or more was observed. This was only the case in 
one of the seven patients in whom the dosing interval was kept at eight hours (Fig 
2). This difference was statistically significant (p<0.05). 
DISCUSSION 
In patients with CF, the pharmacokinetics of a number of drugs, including 
aminoglycoside and B-lactam antibiotics, deviate form normal (15). Since patients 
with CF have a greater Total Body Clearance of aminoglycosides, the use of 
current dosing nomograms in these subjects may result in gross overdosing and 
especially underdosing (8, 16). This study presents data which correlate predose 
serum tobramycin concentrations with clinical outcome in the routine treatment 
of acute pulmonary exacerbations due to P.aeruginosa in patients with CF. A 
significant direct relationship was found between predose serum tobramycin 
concentration and change in FEV,. This indicates that the outcome of treatment 
with tobramycin in CF is highly dependent on the time during which effective 
serum and, hence, tissue concentrations are maintained. Our finding suggests a 
need for an altered dosing regimen in patients with low predose serum tobra-
mycin concentrations and provides a simple means of improving the efficacy of 
antibiotic treatment in patients with cystic fibrosis. Adjustment can be either 
85 
achieved by increasing the dose per administration or by shortening the dosing 
interval. Increasing the dose implies a higher peak serum concentration of 
tobramycin (i.e., the serum concentration of tobramycin immediately after the 
infusion). In an animal model, a linearity was shown between concentrations of 
aminoglycosides in perilymph and the size of the doses injected (17). Division of 
doses in order to diminish high peak concentrations resulted in less ototoxicity 
(17). In order to prevent toxic side effects of tobramycin and in view of the 
achieved one-hour serum concentrations of tobramycin in our patients with CF (a 
one-hour serum tobramycin concentration between 6 and 8 mg/1 may be 
regarded as safe and efficacious) (18), we decided not to increase the dose per 
administration but to shorten the dosing interval. The risk of drug retention is least 
if the serum concentration of tobramycin prior to each dose is less than 2 mg/1 
(19). A concentration of 1 mg/1 is able to inhibit the in vitro growth of about 90 
percent of the isolates of P. aeruginosa from patients with CF (20). It may be 
assumed that given this concentration in the serum, the bioactive concentration 
of tobramycin in the bronchial tree will be considerably lower (21). To avoid 
accumulation, as well as unnecessarily low serum concentrations for a 
considerable part of the dosing interval, we started to adjust the dosing regimen 
of tobramycin in patients with CF to a predose serum tobramycin concentration 
of approximately 1 mg/1. In this study, adjustment was carried out after ten days 
of treatment. Routinely, it will be more appropriate to have an evaluation of 
dosage after the fifth or sixth administration (steady-state phase). When pharma-
cokinetic data justify it, use of more frequent dosages should then be undertaken 
in order to rule out subtherapeutic serum concentrations of tobramycin as a 
cause for therapeutic failure. 
The objective of antimicrobial treatment is to contain the infection. A reduction in 
infection results in a better patency of the airways and therefore leads to a better 
gas exchange (22). The FEV1 is a reliable and reproducible measure of the caliber 
of the airways. In CF, the FEV1 has proven to be an index that more closely 
reflects clinical improvement over a short period of time than other indices such 
as fever, white blood cell count, chest roentgenogram, or bacteriologic results 
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(23). This is in accordance with our own experience. The FEV, was therefore 
taken as an indicator for the effect of treatment. On the 20th day, seven of the 
nine patients who had been treated at shortened dosing intervals showed a 
significant increase in FEV, compared to the value measured on the tenth day. No 
such increase was observed for the other two patients. This could not be 
attributed to lower baseline pulmonary function or more severe disease state as 
assessed by the Schwachman scoring system (24). 
Tobramycin was administered in combination with ticarcillin. The dosing regimen 
of ticarcillin was the same for all patients. The strains of P.aeruginosa isolated 
from the patients' samples of sputum were susceptible to both antibiotics (MIC 
of tobramycin, ..s_2 mg/1; MIC of ticarcillin, ..s_64 mg/1)(25). Initial susceptibility of 
the organisms to either antibiotic was not related to the improvement in FEV,. In 
vitro interaction between tobramycin and ticarcillin against the strains was not 
investigated. The clinical relevance of in vitro interaction is still insufficiently defined 
(26). The reason for combined treatment was that resistance has been observed 
to emerge less often with combined therapy (27). 
No side effects of tobramycin were observed in patients involved in the present 
study. Among other patients in whom the dosing interval was adjusted, 
accumulation of tobramycin was seen in one patient. Renal function improved 
after cessation of therapy. In a second patient, audiograms showed changes at 
high frequencies. This once again emphasizes the need to determine regularly the 
one-hour and trough serum concentrations of tobramycin (for instance, twice per 
week), as well as renal and auditory functions (for instance, once per week) in 
order to monitor accumulation and toxicity. 
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SUMMARY 
Patients with cystic fibrosis (CF) show abnormal aminoglycoside pharmaco-
kinetics. After a conventional dose, the serum concentrations in CF patients are 
lower than those in non-CF patients. The lower serum concentrations in CF might 
be explained by increased total body clearance andjor a larger volume of 
distribution. The therapeutic range of aminoglycosides is narrow due to oto- and 
nephrotoxicity. The changed pharmacokinetics and the narrow therapeutic range 
make it difficult to ensure that patients with CF are adequately and safely treated 
with aminoglycosides. The mode of administration of aminoglycosides influences 
the antibacterial effect of these agents on Pseudomonas aeruginosa and the 
development of possible side effects. The therapeutic implications of these facts 
are discussed. 
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AMINOGl YCOSIDES 
Structure 
Aminoglycosides (1 ,2) consist of two or more aminosugars which, via a glycosidal 
bond, are bound to a central hexose or aminocyclitol molecule. Aminoglycosides 
are natural products isolated from cultures of Micromonospora and Streptomyces. 
Several derivatives have been synthesized from these products in order to 
enhance the antimicrobial range, reduce the toxicity and give the compounds 
better protection from enzymes able to inactivate aminoglycosides. 
Antimicrobial activity 
The antimicrobial activity of aminoglycosides (2) is based on the inhibition, on the 
ribosomal level, of bacterial protein synthesis. Aminoglycosides are bactericidal, 
their range of activity generally encompassing aerobic Gram-negative rods, 
staphylococci and some mycobacteria. Different aminoglycosides can differ in 
antimicrobial activity. In vitro studies have shown that tobramycin is more effective 
against P. aeruginosa than, in decreasing order, amikacin, gentamicin and 
netilmicin (2-4). The bactericidal effect of aminoglycosides on P. aeruginosa is 
greatly concentration-dependent (5,6): the higher the concentration, the quicker 
and more efficient the bacterial population is killed. In this respect, 
aminoglycosides differ from the B-lactam antibiotics in that the bactericidal effect 
is related to the duration of the presence of an effective concentration (>MIG). 
Another difference between aminoglycosides and B-lactam antibiotics used 
against P. aeruginosa is the so-called Post Antibiotic Effect (PAE) (5). After 
exposure of a P. aeruginosa population to an aminoglycoside during a given time, 
growth is not immediately resumed after discontinuation of the agent; it remains 
suppressed for some time. The duration of this continued suppression depends 
on the aminoglycoside concentration and the duration of the exposure. B-lactam 
antibiotics except imipenem do not show any PAE when used against P. 
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aeruginosa. Aminoglycoside concentrations lower than the Minimum Inhibitory 
Concentration (sub-MICs) may also have a morphological and quantitative effect 
on a bacterial population (5). P. aeruginosa growth has been demonstrated to be 
delayed by sub-MICs of aminoglycosides. 
Aminoglycosides activity can be influenced by exogenous factors. The 
antimicrobial activity of aminoglycosides is diminished, for instance, in the 
presence of sputum (7-9). Moreover, inactive amide compounds can be formed 
with penicillins aimed against P. aeruginosa (10). The extent to which this 
happens differs from one aminoglycoside to the other (1 1). Tobramycin is 
inactivated more markedly than, in decreasing order, gentamicin, netilmicin or 
amikacin. In terms of laboratory technique, this means that an aminoglycoside 
concentration in samples from patients also receiving a penicillin should be 
analyzed soon after sampling (1-2 hours). If this is not feasible, then the sample 
should be stored at -70°C until analysis (11). The formation of amide compounds 
is believed to be of little clinical significance because the time required to form the 
compound exceeds the half-life time (tJ of the individual agents (12). This would 
be of importance in the case of disturbed renal function, with increased half-life 
times. 
Pharmacological properties 
Aminoglycosides (1, 13) are stable, weakly basic, water-soluble compounds. They 
are not absorbed from the intestines and can therefore only be given parenterally. 
After administration, they are distributed over the extracellular compartments. In 
the human body, aminoglycosides are not metabolized, show hardly any protein 
binding, and are excreted by the kidneys by glomerular filtration. A small 
percentage of the filtrated fraction is reabsorbed by the proximal tubules of the 
kidney. In healthy individuals, the creatinine clearance, therefore, exceeds that of 
the aminoglycoside. 
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Toxicity 
The major side effects of aminoglycosides involve the kidney and the ear (14,15). 
Toxicity is based on accumulation. In the kidney, a fraction of the aminoglycoside 
dose in the ultrafiltrate is taken up by the proximal renal tubules via carrier-
mediated pinocytosis (14,16,17). This implies that the actual pinocytosis is 
preceded by the binding of the aminoglycoside to a carrier: acid phospholipids 
localized in the brush border. This binding is a low-affinity large-capacity system. 
Since this system is saturable, low concentrations in the ultrafiltrate are 
reabsorbed more effectively than high concentrations. This means that of an 
aminoglycoside dose given by bolus injection, less is stored in the renal cortex 
than would be stored if the same dose was administered over the dose interval 
by continuous infusion. The mode of administration may also influence the 
accumulation in the labyrinth (18). The nephrotoxic effect is manifested by 
proteinuria, reduced glomerular filtration, and excretion of certain tubular enzymes 
(14). Renal function usually shows gradual recovery after discontinuation of 
therapy. Cochlear ototoxicity (15) is manifested by permanent degeneration of hair 
cells in the organ of Corti, starting in the high-pitch region of the basilar 
membrane. As a result of accumulation in the labyrinth, the degenerative process 
may continue for considerable length of time after stopping therapy. Vestibular 
ototoxicity (15) also occurs, but the patient is able to compensate for this 
disturbance so that vestibular lesions are less serious than cochlear damage. 
The individual agents are thought to differ in toxicity (15, 19,20). Netilmicin is 
believed to be the least ototoxic agent. It has been established empirically that the 
risk of toxic effects increases when (as a consequence of reduced renal function) 
the trough concentration starts to exceed a certain threshold value (21). The 
maximum trough value for gentamicin and tobramycin is believed to be 2 mgjl, 
for netilmicin 3 mg/1, and for amikacin 5 mgjl. 
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Pharmacokinetics 
The pharmacokinetic behavior of aminoglycosides is best described on the basis 
of a 3-compartment model (22). The serum concentration-time curve is 
characterized by a phase of distribution (a) and a fast (/3) as well as a slow (Y) 
phase of elimination. During the phase of distribution, the serum aminoglycoside 
concentration is determined largely by its flow into the tissues, and to a lesser 
extent by its renal excretion. Once a balance between blood and tissues is 
attained, the course of the serum aminoglycoside concentration is largely deter-
mined by renal function. Given normal renal function, the half-life of the fast phase 
of elimination is about 2 hours (23). During the slow phase of elimination, which 
manifests itself in a concentration-time curve about 24 hours after discontinuation 
of therapy, the excretion depends on the amount of aminoglycoside supplied to 
the kidneys. This involves the slow release of very low concentrations from the so-
called deep compartments, including the labyrinth and the renal cortex. The half-
life of the 'Y-phase is a few days (23). 
Reports vary on the amount of aminoglycoside which penetrates into the 
bronchial secretions: the values found range from 10 to 70% of the serum 
concentration (13,24). 
AMINOGL YCOSIDES AND CYSTIC FIBROSIS 
introduction 
Thirty to 50% of the younger and 70-90% of the older patients with cystic fibrosis 
(CF) have a chronic pulmonary infection caused by P. aeruginosa (25). Acute 
exacerbations are commonly treated with an aminoglycoside in combination with 
an anti-pseudomonas B-lactam antibiotic (26). 
There are indications that the pharmacokinetics of some of these agents deviate 
from normal in CF (27). The drugs in question have to be given more frequently 
or in a higher than usual dose in order to ensure sufficiently protracted active 
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serum concentrations_ The lower serum concentrations following a conventional 
dose could be explained, according to pharmacokinetic studies of 
aminoglycosides in CF patients, by an increased Total Body Clearance (TBC) 
andjor a larger Volume of distribution (Vd) (27). Most studies report an increased 
TBC of aminoglycosides in CF patients (Tables 1 and 2). Reports of an increased 
Vd in CF patients are less consistent (Tables 1 and 2). This may be due, on the 
one hand, to the fact that the Vd generally shows a greater interpatient variability 
(41), and, on the other hand, to the fact that the Vd value found depends on the 
state in which it is measured (non-steady state vs steady state) (42). The definition 
of the Vd also proves to have an influence. Levy et al (36) and Vogelstein et al 
(39) found increased Vd of tobramycin and amikacin, respectively, if it was 
expressed in ijkg. When calculated using body surface area, the Vd in CF 
patients was not significantly different from that in nonCF patients. This may have 
been due to an increased extracellular volumejbody weight ratio in CF (whereas 
the extracellular volumejbody surface area ratio is unchanged) (24). With regard 
to Table 1, the investigators compared their CF data with nonCF data from other 
studies. Consequently, differences in Vd (and TBC) may have resulted from 
differences in techniques used. 
Total Body Clearance 
The TBC can be calculated independent of the model by dividing the dose by the 
Area Under the concentration-time Curve (AU C) (43). The proportion of the dose 
which enters the system after intravenous administration can be estimated as 
virtually 100%. The accuracy with which the AUC can be determined increases 
with an increasing number of samples (blood samples in which the concentration 
is measured). In nonCF patients, 100% of a total dose of aminoglycoside 
administered is excreted in the urine, and release from the deep compartments 
continues for some considerable time after discontinuation of therapy (23). An 
increased TBC of aminoglycosides in CF patients could be the result of increased 
renal excretion due to increased filtration andjor diminished tubular reabsorption. 
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Levy et al (36) found an increased TBC of tobramycin in CF patients compared 
with controls, but this was not associated with increased renal clearance. This 
suggested that, in CF, there must be other than renal pathways for clearance of 
tobramycin (in bile or sputum). Metabolization of tobramycin in CF was also 
suggested. It should be borne in mind, however, that Levy et al (36) made their 
measurements after the third dose a situation in which a steady state of 
equilibrium is not yet attained. Unsaturated tissues attract a larger proportion of 
an aminoglycoside dose than saturated tissues. This implies that, as the tissues 
become more saturated, an increasing proportion of a dose is cleared in the urine 
per unit of time (42). The larger TBC in CF patients in the study of Levy et al (36) 
might therefore also be explained by differences in tissue saturation between CF 
patients and nonCF patients. Unlike Levy et al (36) with tobramycin, Vogelstein 
et al (39) found an increased renal clearance and a larger TBC of amikacin in CF 
patients (after the fourth dose). Michalsen et al (37) were unable to demonstrate 
differences in netilmicin renal clearance and TBC between CF patients and nonCF 
patients (after a single dose). The suggestion of Levy et al (36) that extrarenal 
clearance pathways could be responsible for the larger TBC of tobramycin in CF, 
was regarded as unlikely for gentamicin by MacDonald et al (29). They found 
more than 80% of the gentamicin administered in the urine within 4 hours after 
infusion of a single dose. We made a similar observation for tobramycin (Table 3). 
Renal function measured from glomerular filtration and tubular excretion has been 
thoroughly studied in CF and found not to differ from that in control subjects (44). 
The tubular resorption to which aminoglycosides are subject has not been 
adequately investigated so far. Should this be diminished in CF, then this implies 
that less of the drug is stored in the proximal tubules of the kidneys. An indication 
of this can be found in a study reported by Rabin et al (45) in which they found 
a shorter t'h'Y for tobramycin (63 hours in CF, vs 146 hours in nonCF patients), 
which suggests an altered exchange of aminoglycosides between blood and 
tissues in these patients. 
Possible extrarenal clearance of an aminoglycoside in CF can be investigated 
simply by collecting all samples of urine during and for some time after therapy, 
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Table 3-Urinary Elimination of a Single Dose of 
Tobramycin (2 mglkg) in Patients with CF 
Percentage of dose 
recovered within 
Patients 3to6hrs 
N after infusion 
1 78 
2 90 
3 79 
4 80 
5 85 
6 77 
7 85 
8 78 
Table 4-Relationship of Aminoglycoside Pharmacokinetic 
Parameters vs Age, Body Weight and Severity of Disease in 
CF 
Patients Renal 
N TBC* Clearance Vdt Reference 
Gentamicin 
Age/BW 7 +:J: + -:j: MacDonald et al29 
12 Mann et al35 
Severity of 8 + ±a MacDonald et al29 
disease 
Tobramycin 
Age/BW 15 + + Horrevorts et al30 
52 + + Hsu et al47 
11 MacDonald et al49 
17 Mann et al35 
Severity of 15 Horrevorts et al30 
disease 11 + + MacDonald et al49 
*Total body clearance 
tVolume of distribution 
:j: +:correlation; ±:weak correlation; -:no correlation 
. . . Not available 
and measuring the total recovery of the aminoglycoside in the urine. If there is 
extrarenal clearance, then this should be clearly less than complete. 
Volume of Distribution 
The Vd is the volume attained at a steady state condition. Some of the differences 
in Vd between different studies must be due to the fact that most were performed 
in a nonsteady state pharmacokinetics. In this state, the tissue compartments are 
either not or only partially loaded, and in any case studies differ in the degree of 
loading. With regard to aminoglycosides, a system is not completely loaded until 
therapy has been given for about 5 times the t;; (43). Since the t;; of amino-
glycosides is several days, this means many days of therapy. Comparative phar-
macokinetic steady state studies offer the only chance to discover whether the Vd 
of aminoglycosides in CF patients does indeed exceed that in control subjects. 
However, if in CF there is clearance of aminoglycosides which bypasses the 
central compartment (in sputum, for instance), then a pharmacokinetic balance 
could not be attained and the Vd at steady state of equilibrium could not be 
measured (46). 
T;; Elimination 
The t;; ( =1;;6) elimination is a model-dependent parameter influenced by both the 
TBC and the Vd (1;; elimination""Vd/TBC) (43). As pointed out, the pharmacoki-
netics of aminoglycosides can best be described on the basis of a 3-compartment 
model. With a 1-compartment model the t;; elimination can be a mixture of 
distribution and elimination, and with a 2-compartment model it can be a mixture 
of elimination and return from the deep compartments. In the former, the value 
found fort;; elimination can be too small, and in the latter, it can be too large. The 
method used, therefore, can influence the half-life. Since t;; elimination""Vd/TBC, 
in studies disclosing both larger Vd and larger TBC values for CF, in reality the t;; 
will not differ much from that of controls (Table 2). In studies in which the TBC is 
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increased but not the Vd, however, the ~ elimination found in CF may be smaller 
(Table 2). 
lnterpatient Variability 
The pharmacokinetic parameters of aminoglycosides would seem to show greater 
variability in CF patients than in nonCF patients. This may be due to inter-patient 
differences in age and in severity of disease. A number of studies have sought to 
find a correlation between TBC on the one hand, and age and severity of disease 
on the other. A summary of findings is presented in Table 4. Unlike Horrevorts et 
al(30), Hsu et al(47), and MacDonald et al (29), Mann et al (35), were unable to 
demonstrate a correlation between TBC and age; in their study, however, 
interpatient variability in the control group was at least as marked as in the CF 
group. Age dependence of the TBC of tobramycin in children with CF was found 
also in children without CF (Hoecker et al) (48). In the study of Hoecker et al (48) 
-as in those of Horrevorts et al (39), Hsu et al (47) and MacDonald et al (29)- the 
TBC of the aminoglycoside studied increased with increasing age. MacDonald et 
al (29) were the only investigators to suggest a correlation between de TBC of 
gentamicin and the severity of the disease (NHI score). 
Correlations between Vd on the one hand and age or severity of disease on the 
other, are far less evident (29,49). 
THERAPEUTIC IMPLICATIONS 
Introduction 
The preceding sections have discussed the antimicrobial action of amino-
glycosides against P. aeruginosa, the side effects of these agents and their 
deviant pharmacokinetics in patients with CF. The implications of these findings 
with regard to adequate and safe aminoglycoside therapy for CF patients will now 
discussed focussing on the aminoglycoside tobramycin. 
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Points of importance in the treatment of infections include: a) the susceptibility of 
the microorganism to the antibiotic used; b) the concentration of the agent that 
can be attained at the site of infection. In our CF population, the MIC50 and MICoo 
(Minimum Inhibitory Concentrations required to inhibit the growth of 50 and 90% 
respectively of the total number of strains tested) of tobramycin against P. 
aeruginosa are 1 mgjl and 2 mgjl respectively (50). In a previous study, we have 
investigated the pharmacokinetic behavior of tobramycin in 15 patients with CF; 
we followed the course of the serum tobramycin concentration after administration 
by iv infusion of 3.3 mgjkg over 8 hours (51). The study was performed after the 
patients had already received more than 25 such doses. The concentrations 
measured in the serum samples obtained immediately after the infusion (t=20 
min) and 60 min, 4 hours and 8 hours after the start of the infusion, were (mean 
± SO): 11.6±3.3 mgjl, 5.4± 1.0 mgjl, 1.4±0,6 mgjl, and 0.5±0.2 mgjl. The 
serum tobramycin concentrations measured 20 and 60 minutes after the start of 
the infusion exceeded the MIC90 of tobramycin against the CF Pseudomonas 
isolates in all patients. Four hours after the start of the infusion a number of 
patients showed serum tobramycin concentrations lower than the MIC50• This 
means that in some patients the serum tobramycin concentration is below the 
MIC of the aminoglycoside against CF Pseudomonas isolates during a large part 
of the dose interval. Bioactive tobramycin concentrations at the site of infection 
may be assumed to be lower than serum concentrations (9). Since the 
bactericidal activity of tobramycin against P. aeruginosa is highly concentration-
dependent, intermittent administration is preferable to administration by 
continuous infusion. Following intermittent administration, serum concentrations 
are high for a short time after administration. Studies in CF patients have shown 
that the serum tobramycin concentration 1 hour after administration correlated 
with clinical and bacteriologic response (42,45). Attempts should be made to 
ensure 1-hour concentrations between 6 mgjl and 12 mg/1 (53). Also with regard 
to side effects, intermittent administration is preferred above continuous infusion. 
It has been established empirically that trough concentrations of tobramycin 
exceeding 2 mgjl increase the risk of toxic side effects. This value gives an 
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indication of the length of the dose interval. This should be sufficiently long to 
ensure that the concentration decreases to below 2 mg/1 after a dose. On the 
other hand, dose intervals during which the concentration is below 2 mgjl for a 
proportionally long time should be avoided. Low concentrations contribute little 
to effectiveness, but they do increase the risk of accumulation and therefore of 
toxicity. An earlier study has shown that a reduction of the dose interval based on 
a trough concentration of about 1 mgjl produced a better clinical response than 
a dose interval in which the concentration was below 1 mg/1 for a considerable 
time. This may be due to the fact that by giving more frequent administrations, the 
benefit of high concentrations immediately after administration is enjoyed several 
times. Another explanation might be that during prolonged low concentrations, 
growth of the microorganisms nevertheless resumes. This can therefore be 
reduced by shortening the dose interval. 
Treatment 
In view of the marked interpatient variability, the dosage and the frequency of 
administration should be adjusted individually. Dosage should aim at 1-hour 
concentrations between 6 mgjl and 12 mg/1. Determination of the dose interval 
should aim at trough concentrations below 2 mg/1. The minimum trough 
concentration adhered to at the Sophia Children's Hospital is 1 mgjl. In view of 
the narrow therapeutic range of tobramycin, 1-hour and trough concentrations 
should be measured regularly, as should auditory and renal functions. The acute 
and chronic toxicity of repeated-dose tobramycin treatment in patients with cystic 
fibrosis seems to be very mild (54,55). 
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SUMMARY 
Cystic fibrosis (CF) is the most common inherited disease among white 
Caucasians. The condition is transmitted as an autosomal recessive trait and 
heterozygotes do not express the disease. CF affects exocrine gland secretions 
throughout the body. Clinically, it is characterized by exocrine pancreatic insuf-
ficiency and chronic obstructive pulmonary disease. Pulmonary infection is the 
major cause of morbidity and mortality. 
The microorganism most frequently isolated from CF sputum is P. aeruginosa. 
Once acquired, this organism is seldom eradicated, although it may disappear 
temporarily from the sputum during treatment. From single sputum samples, 
isolates of P. aeruginosa with differing morphological characteristics and 
antibiograms can be cultured. These observations together with reported 
difficulties in typing CF isolates resulted in confusion about the number of types 
which might colonize an affected individual. Some reports have suggested that CF 
patients may be colonized by a single type, while others reported colonization by 
two or more different types. These contradictory results might be explained by the 
limitations of the typing techniques per se as well as by the peculiar properties of 
P. aeruginosa which affect the methods. In particular the mucoid character and 
the poly- and nontypability in serotyping appear to account for most of the 
inconsistent observations. In chapter 1 several typing techniques were evaluated 
for their potential as epidemiological tools for isolates of P. aeruginosa from CF 
patients. Apart from the confusion about the number of types which might 
colonize an individual patient, it is conceivable, that the type or types present in 
the lungs during the course of time will be replaced by another type or types. In 
chapter 2 a study is described in which the composition of the pseudomonas 
flora was monitored over a period varying from 2 to 60 months in fifteen patients 
with CF aged between 7 and 18 years. Four conventional typing techniques were 
used, namely serotyping, active and passive pyocin typing, and phage typing. The 
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aim of the study was to establish whether the composition of the flora of P. 
aeruginosa in the lungs of individual patients is subject to changes or whether it 
remains constant over time. The number of different serotypes per patient ranged 
from one to three, and pyocin and phage typing showed no marked differences 
between strains of the same serotype. In general, patients whose sputum yielded 
more than one type harbored these in several samples. An exacerbation of the 
chronic respiratory infection did not affect the composition of the flora. long term 
observations showed that a given type or types tended to recur supporting the 
conclusion that the composition of the pseudomonas flora in CF remains fairly 
constant over time. 
During the last few decades antimicrobial therapy has significantly improved the 
prognosis of CF by reducing the progression of pulmonary destruction. In some 
centers only acute exacerbations are treated while in others, patients are given 
antimicrobial therapy periodically or even continuously. At present many 
antipseudomonas drugs are available for this purpose. In vitro assessment of 
these agents against P. aeruginosa recovered from sputum of patients with CF 
showed that on a weight basis ciprofloxacin was the most active agent tested 
(chapter 3). At clinically attainable serum concentrations tobramycin and amikacin 
had similar activity. If resistance to a B-lactam agent occurred, cross resistance 
to other B-lactams was the rule. 
Exacerbations of chronic respiratory infections caused by P. aeruginosa are 
usually treated with an aminoglycoside in combination with an. antipseudomonas 
B-lactam antibiotic or a quinoline. Combination therapy is often given because it 
seems to offer better results than those obtained from monotherapy, possibly due 
to synergistic interaction in relation to P. aeruginosa. Furthermore, resistance to 
combination therapy is believed to develop less rapidly. The in vitro interaction 
between tobramycin on the one hand and three antipseudomonas B-lactam 
antibiotics on the other was investigated by means of checkerboard titrations 
(chapter 4). Special attention was paid to the influence of the composition of the 
dilution series on the outcome by comparing twofold and modified serial dilutions 
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of the antibiotics. Consecutive concentrations in these modified serial dilutions 
were four times smaller than those in the twofold series permitting minimum 
inhibitory (MICs) and minimum bactericidal (MBCs) concentrations to be 
determined with greater accuracy. More accurate determination of MICs and 
MBCs will be reflected in parameters derived from them such as the fractional 
inhibitory (FICis) and fractional bactericidal (FBCis) concentrations indices which 
are a measure of drug interaction. It was shown that the indices (twofold versus 
modified serial dilutions) can differ markedly (from -0.30 to + 1.06). Thus, the inter-
pretation of these data depends also on the composition of the serial dilutions 
used. The theoretical background of this observation is discussed in chapter 5. 
In CF patients, the pharmacokinetics of several antimicrobial agents, including 
aminoglycosides and B-lactam antibiotics, differ from those observed in the normal 
individual. The agents in question are believed to be excreted more rapidly in this 
disease. Therefore, these drugs have to be given more frequently and in a larger 
dose in order to ensure that therapeutic concentrations are achieved and 
maintained for a sufficient duration at the infection site. In view of their oto- and 
nephrotoxicity aminoglycosides have a limited therapeutic range. To be adequate 
and safe, treatment of CF patients with these drugs has to fulfil strict criteria. The 
steady-state pharmacokinetics of tobramycin in fifteen patients with CF aged 
between 8 and 22 years are reported in chapter 6. In the calculation of 
pharmacokinetic parameters, a two-compartment open model was used. It was 
shown that the serum tobramycin concentration-time profile changes with age, in 
so far as with increasing age the distribution phase converts more rapidly to the 
elimination phase and in addition, elimination shows a faster decline. The half-
lives of the distribution {a) and elimination (f3) phases were inversely correlated 
with age and body weight (t'h<Z versus BW; r.=-0.81, p<0.0005 and t>~a versus BW; 
r.=-0.88, p<0.00005). So was the ratio of the Area Under the Curve to the dose 
(AUC/dose versus BW; r.=-0.76, p<0.005), while Total Body Clearance (TBC 
versus BW; r.= +0.66, p<0.01) and Volume of distribution at steady state (Vdss 
versus BW; r.= +0.53, p<0.05) were directly correlated. Between patients, no 
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marked differences were observed in the height of the one hour serum 
tobramycin concentrations, whereas considerable differences were found in the 
height of the serum tobramycin concentrations prior to the next dose (trough 
concentrations). This wide interpatient variation could have clinical implications for 
tobramycin therapy in CF, particularly for the dosing interval. In chapter 7 we 
investigated whether this variation determined the outcome of treatment. Twenty 
eight patients with an acute exacerbation of chronic pulmonary infection with P. 
aeruginosa were treated with tobramycin (3.3 mgjkg every 8 hours) in 
combination with ticarcillin (600 mgjkgjday). On the tenth day of treatment a 
significant correlation (r.= +0.75, p<0.001) was found between trough serum 
tobramycin concentration and increase in Forced Expiratory Volume in 1 second 
(FEV1). In sixteen patients the increase in FEV1 was less than twenty percent. To 
achieve a higher trough level, the dosing interval was shortened in nine of these 
sixteen patients; hence the 24 h dosage was increased. On the 20th day of 
treatment, FEV1 had improved by at least twenty percent in seven of the subjects 
in whom the dosing interval was shortened, but in only one of those in whom the 
interval remained unchanged (p<0.05). Therefore, individualization oftobramycin 
dosage in CF results in a better clinical outcome. 
The implications of the pharmacological data described in the chapters 6 and 7 
are discussed in chapter 8 in the light of current opinions on treatment with 
aminoglycosides of acute P. aeruginosa exacerbations in patients with cystic 
fibrosis. 
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SAMENVATTING 
Cystic fibrosis (CF) is de meest voorkomende autosomale recessieve erfelijke 
ziekte onder het blanke ras. De pathogenese van CF is terug te voeren op 
afwijkingen in de secreten van exocriene klieren. De belangrijkste 
ziekteverschijnselen van CF vinden hun oorsprong in de tractus digestivus en de 
tractus respiratorius. De morbiditeit en mortaliteit van CF worden voor het 
merendeel bepaald door infekties van de luchtwegen. 
Pseudomonas aeruginosa is het micro-organisme dat het meest frekwent uit 
sputa van patienten met CF wordt ge"isoleerd. Wanneer dit micro-organisme 
eenmaal in het sputum van een patient is aangetroffen, verdwijnt het daaruit 
slechts zelden. In sputumkweken van CF patienten kunnen meerdere 
kolonievormen van P. aeruginosa worden aangetroffen. De gevoeligheid voor 
antimicrobiele middelen kan per kolonievorm verschillend zijn. Deze bevindingen 
tezamen met problemen rand het typeren van CF stammen hebben geleid tot 
verwarring over het aantal typen waarmee een CF patient gekoloniseerd kan zijn. 
Sommige studies maken melding van de aanwezigheid van slechts 1 type, andere 
van 2 of meer. Deze tegenstrijdige bevindingen zouden enerzijds kunnen 
samenhangen met de beperkingen van de typeringstechnieken op zich, terwijl 
anderzijds het typeren van P. aeruginosa stammen afkomstig van CF patienten 
wordt bemoeilijkt door speciale kenmerken welke deze stammen kunnen bezitten, 
zoals de produktie van een mukeus exopolysaccharide, en door veranderingen 
in het lipopolysaccharide van de buitenmembraan. In hoofdstuk 1 wordt de 
bruikbaarheid van een aantal typeringstechnieken voor het typeren van 
Pseudomonas-isolaten van patienten met CF besproken. 
Afgezien van onduidelijkheden over het aantal P. aeruginosa typen dat in 
sputummonsters van CF patienten kan worden gevonden, is het denkbaar dat in 
de tijd gezien stammen van verschillend type elkaar opvolgen. In hoofdstuk 2 is 
de samenstelling van de Pseudomonasflora bij 15 patienten (leeftijden van 7-18 
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jaar) over perioden varierend van 2-60 maanden in kaart gebracht. Hierbij zijn de 
volgende typeringsmethoden gebruikt: de serotypering, de aktieve - en passieve 
pyocinetypering en de faagtypering. Het doel van de studie was nate gaan of de 
Pseudomonasflora in de Iangen van CF patienten in de tijd constant of wisselend 
van samenstelling is. Het aantal gevonden serotypen varieerde bij de patienten 
van 1 tot 3. Tussen stammen van hetzelfde serotype werden, per patient, geen 
grate verschillen in het pyocine- en het faagtype gevonden. Bij patienten met 
meer dan een serotype werden de verschillende typen in het algemeen in 
meerdere sputummonsters aangetroffen. Een exacerbatie bleek de samenstelling 
van de Pseudomonasflora niet te be"invloeden. De typeringsresultaten tesamen 
Iaten zien dat de samenstelling van de Pseudomonasflora in de luchtwegen van 
patienten met CF in de tijd vrijwel constant is. 
De prognose van CF is in de loop van de laatste decennia geleidelijk verbeterd. 
Daar de chronische ontsteking de voornaamste determinant van de prognose is, 
is de verbeterde prognose voor een belangrijk deel te danken aan de 
antimicrobiele therapie. In bepaalde centra worden uitsluitend akute exacerbaties 
behandeld. In andere daarentegen worden periodiek (wei of geen exacerbatie) of 
zelfs kontinu antimicrobiele middelen gegeven. Tegenwoordig zijn er vele 
preparaten met een antimicrobiele werking ten opzichte van P. aeruginosa op de 
markt. In hoofdstuk 3 is de in vitro gevoeligheid van P .aeruginosa stammen 
ge"isoleerd uit sputa van patienten met CF bepaald voor een aantal van deze 
middelen. Ciprofloxacin bleek, op basis van het gewicht aan droge stof, het meest 
aktieve middel. Tobramycine en amikacine hadden, afgemeten aan de 
gebruikelijke serumconcentraties van elk, een overeenkomstige antibakteriele 
werking. Kruisresistentie tussen de onderzochte B-lactam antibiotica kwam in de 
regel voor. 
Exacerbaties van een chronische luchtweginfektie door P. aeruginosa worden 
bij CF meestal behandeld met een aminoglycoside in kombinatie met een tegen 
Pseudomonas aktief B-lactam antibioticum of quinolon. Een dergelijke kombinatie 
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wordt vaak gegeven omdat deze (mogelijk door een synergistische interactie t.o.v. 
P. aeruginosa) tot betere resultaten leidt dan monotherapie. Bovendien zou door 
gekombineerde therapie minder snel resistentievorming optreden. In hoofdstuk 
4 wordt ingegaan op de in vitro interaktie tussen het aminoglycoside tobramycine 
enerzijds en een drietal tegen P. aeruginosa werkzame B-lactam antibiotica 
anderzijds. De interakties zijn bestudeerd met behulp van schaakbordtitraties. 
Onderzocht is met name of de samenstelling van antibiotikumverdunningsreeksen 
van invloed is op het uiteindelijke resultaat. Hiervoor zijn tweevoudig verdunde 
reeksen vergeleken met gemodificeerd verdunde reeksen. Van deze laatste zijn 
de stappen tussen elkaar opvolgende concentraties vier maal kleiner dan die van 
tweevoudig verdunde reeksen. Hierdoor is het mogelijk de minimaal remmende 
(MRCs) en de minimaal bactericide (MBCs) concentraties nauwkeuriger te 
bepalen. Dit moet dan ook gelden voor parameters (als de fraktionele remmende 
concentratie- en de fraktionele bactericide concentratie indices) die een maat zijn 
voor de interaktie tussen twee antibiotica aangezien deze aan de hand van 
respectievelijk de gevonden MRCs en .MBCs berekend worden. Uit de studie 
bleek dat tussen de interactie indices van de tweevoudig verdunde reeksen en 
de gemodificeerd verdunde reeksen aanzienlijke verschillen kunnen bestaan (van -
0.30 tot + 1.06). Dit leidde tot de conclusie dat de interactie indices mede worden 
bepaald door de samenstelling van de gebruikte antibioticumverdunnings-reeksen. 
De theoretische achtergrond en praktische betekenis hiervan zijn besproken in 
hoofdsfuk 5. 
De farmacokinetiek van een aantal antimicrobiele middelen, waaronder 
aminoglycosiden en B-lactam antibiotica, wijkt bij patienten met CF af van de 
norm. De betreffende middelen worden bij patienten met CF sneller uitgescheiden. 
Derhalve worden ze vaker en in een hogere dosis toegediend om te waarborgen 
dat gedurende een voldoende lange tijd op de plaats van infektie concentraties 
aanwezig zijn waarvan verwacht mag worden dat ze therapeutisch effektief zijn. 
Aminoglycosiden hebben in verband met oto- en nefrotoxiciteit een kleine 
therapeutische breedte. Aan een adekwate en veilige behandeling van CF 
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patienten met aminoglycosiden worden dientengevolge hoge eisen gesteld. In 
hoofdstuk 6 is een onderzoek beschreven naar de steady state farmacokinetiek 
van tobramycine bij 15 patienten met CF. De patienten varieerden in leeftijd van 
8 tot 22 jaar. Bij de berekening van de farmacokinetische parameters is uitgegaan 
van een open twee-compartimenten model. Uit de studie bleek dat de 
concentratie-tijdcurve van tobramycine verandert met de leeftijd in die zin dat met 
oplopende leeftijd de verdelingsfase eerder overgaat in de eliminatiefase; 
bovendien gaat de eliminatie sneller verlopen. 
De halfwaardetijden (t,J van de verdelings- (a) en eliminatiefase (/3) bleken 
omgekeerd evenredig te zijn met leeftijd en 1,ichaams,9.ewicht (t,.. vs LG; r. =-
0.81, p<0.0005 en 1,8 vs LG; r.=-0.88, p<0.00005). Dit was ook het geval met het 
Qppervlak Qnder de .Qurve gedeeld door de Qosis (OOC/D vs LG; r.=-0.76, 
p<0.005), terwijl de Iotale 1,ichaams Klaring (TLK vs LG; r.= +0.66, p<O.Oi) en 
het ~er.Qelingsvolume tijdens .§.teady .§.tate (Vdss vs LG; r.= +0.53, p<0.05) 
rechtevenredig waren met leeftijd en gewicht. 
De tobramycine-serumconcentratie 1 uur na de start van de infusie bleek tussen 
patienten niet veel te verschillen. Dit was anders met de concentratie vlak voor 
een volgende gift (dalspiegel). Dit verschil in dalspiegel tussen CF patienten zou 
voor de behandeling met tobramycine gevolgen kunnen hebben, met name voor 
het doseringsinterval. In hoofdstuk 7 is onderzocht in hoeverre de gevonden 
verschillen in dalspiegel van invloed zijn op het klinisch resultaat. Achtentwintig CF 
patienten met een acute exacerbatie van de chronische luchtweginfektie door P. 
aeruginosa werden behandeld met tobramycine (3 x dd 3,3 mgjkg) en ticarcilline 
(600 mgjkgjdg). Tussen de hoogte van de dalspiegel en de stijging van het FEV, 
beide gemeten op dag 10 van de behandeling, bleek een significante correlatie 
te bestaan (r. = + 0. 75, p < 0.01 ). Bij 16 patienten bedroeg de toeneming van het 
FEV, minder dan 20%. Bij 9 van deze 16 patienten is om een hogere dalspiegel 
te krijgen het doseringsinterval van tobramycine vanaf dag 10 verkort (deze 
patienten kregen tobramycine dus vaker per dag toegediend waardoor bij hen de 
totale dagdosis hager werd). Bij de overige 7 patienten is niets aan de toediening 
van tobramycine veranderd. Op de 20e dag van de behandeling bleek bij 7 van 
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de 9 patienten bij wie het doseringsinterval van tobramycine op de 1 o· dag was 
veranderd een toeneming van het FEV1 van meer dan 20% te zijn opgetreden; dit 
was slechts bij 1 van de 7 patienten het geval bij wie het doseringsinterval op de 
1 o· dag van de behandeling niet was verkort. Dit verschil, dat significant bleek 
(p<0.05), betekent dat een klinisch beter resultaat bereikt wordt wanneer bij de 
therapie rekening wordt gehouden met de individuele farmacokinetiek van 
tobramycine. 
De resultaten als beschreven in de hoofdstukken 6 en 7 worden in hoofdstuk 8 
besproken en wei in het Iicht van heersende opvattingen over aminoglycoside-
therapie bij CF patienten met acute exacerbaties veroorzaakt door P. aeruginosa. 
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NAWOORD 
Graag wil ik mijn oprechte dank betuigen aan iedereen die een bijdrage heeft 
geleverd aan de totstandkoming van dit proefschrift, met name: 
Mijn promotores Prof. Dr. M.F. Michel en Prof. Dr. K.F. Kerrebijn voor het 
begeleiden van het onderzoek, hun opbouwende kritiek, hun enthousiasme en 
bovenal hun eindeloos geduld. 
Wijlen Dr. Jan Borst die op zeer persoonlijke wijze zijn specifieke kennis van 
Pseudomonas-bacterien heeft uitgedragen. Hij heeft mij in de gelegenheid gesteld 
om onder de kundige Ieiding van Rob Puyk op zijn afdeling het typeren van 
Pseudomonas-stammen te leren. 
Prof. Dr. C. Hilvering en Prof. Dr. R.P. Mouton, leden van de promotiecommissie, 
voor het beoordelen van het manuscript. 
Dr. John Degener die de basis legde voor dit onderzoek. De dagelijkse Ieiding van 
het project was bij hem in vertrouwde handen. Hij was het die de betekenis van 
de farmacokinetiek voor het onderzoek heeft onderkend. 
Dr. Gordana Dzoljic-Danilovic. Zij is als hoofd van het Bacteriologisch 
Laboratorium van het Sophia Kinderziekenhuis zeer nauw bij het onderzoek 
betrokken geweest. Haar hulp, suggesties en opmerkingen tijdens het onderzoek 
zijn zeer waardevol gebleken. 
Dr. Oscar Driessen. Zijn vermogen voor mij moeilijke farmacokinetische 
vraagstukken op een inzichtelijke wijze uit te leggen was subliem. 
De statistici Dr. J. Hermans en Drs. W. Hop op wier hulp altijd gerekend kon 
worden. 
Dr. Irma Bakker-Woudenberg voor haar inbreng tijdens de werkbesprekingen. Zij 
volgde het onderzoek met grate interesse. 
Ria van Amstel-de Ridder en Nell eke Heeres-Weststrate voor hun analytische hulp 
bij het onderzoek. 
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lneke Vredenberg-Bom die jarenlang de te onderzoeken monsters doorsluisde 
van de afdeling Interne van het Sophia Kinderziekenhuis naar het Bacteriologisch 
Laboratorium. 
De verpleegkundigen van de afdeling Interne van het Sophia Kinderziekenhuis 
(destijds aangevoerd door hoofdzuster Nel Kusters) die mij de naam "A. Tobra" 
bezorgden. 
De physiotherapeuten van het Sophia Kinderziekenhuis voor het kundig afnemen 
van de benodigde sputummonsters. 
Het analytisch personeel van het Bacteriologisch Laboratorium van het Sophia 
Kinderziekenhuis voor het verzamelen van de Pseudomonas-stammen en hun 
hulp bij allerlei bijkomende werkzaamheden. 
Collegae, medewerksters en medewerkers van de afdeling Kinderpulmonologie 
van het Sophia Kinderziekenhuis. 
Marion Poot, Maja de Jonge en Jaap de Witte. Zij hebben tijdens hun studie 
medicijnen in het kader van het keuzevak een bijdrage aan het onderzoek 
geleverd. 
Ada Beukelman, Linda Harkes, Paula Jansen-Bogaars en Carolien van Bakel. Zij 
hebben het onderzoek secretarieel ondersteund. 
Camille van de Zand en Margreet Boeren-den Boer voor het verzorgen van het 
manuscript van het proefschrift. Johan Mouton voor de keuze van het lettertype. 
Peter Donnelly voor het doornemen van het manuscript op onvolkomenheden in 
de Engelse taal. 
De medewerksters en medewekers van het Bacteriologisch Laboratorium van het 
Dijkzigt Ziekenhuis. 
Het Nederlands Astma Fonds dat het onderzoek financieel mogelijk maakte. 
Thea van Vlijmen voor het opschudden van mijn kussen zeer laat op de avond 
en Sophie (mijn oogappel) voor haar levenslust zeer vroeg in de ochtend. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift is geboren te Almelo op 7 november 1949. 
1967 
Eindexamen VWO aan het Pius X College te Almelo. 
1980 
Artsexamen aan de Katholieke Universiteit te Nijmegen. 
1981-1983 
In het kader van een door het Nederlands Astma Fonds gesubsidieerd projekt 
verbonden aan de afdeling Bakteriologie (hoofd Prof. Dr. M.F. Michel) van het 
Akademisch Ziekenhuis Dijkzigt te Rotterdam. In deze periode is gestart met 
het onderzoek dat in dit proefschrift wordt beschreven. Het onderzoek is in 
samenwerking met de afdeling Longziekten bij Kinderen (hoofd Prof. Dr. K.F. 
Kerrebijn) van het Sophia Kinder-ziekenhuis verricht. 
1983-1986 
Opleiding tot medisch-mikrobioloog op de afdeling Bakteriologie (opleider Prof. 
Dr. M.F. Michel) van het Akademisch Ziekenhuis Dijkzigt te Rotterdam. 
1986-1988 
Verbonden als medisch-mikrobioloog aan de afdeling Bakteriologie van het 
Akademisch Ziekenhuis Dijkzigt te Rotterdam. 
1988-heden 
Verbonden als medisch-mikrobioloog aan de afdeling Medische Mikrobiologie 
van het Akademisch Ziekenhuis Sint Radboud te Nijmegen. 
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